Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O

Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O

Their	O
affinity	O
for	O
the	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O

The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	B-cell_type
cell	I-cell_type
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O

The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
(	O
HL-60	B-cell_line
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B-protein
D	I-protein
receptor	I-protein
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B-protein
D-binding	I-protein
protein	I-protein
.	O

The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	B-cell_line
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O

THE	NULL
JOURNAL	NULL
OF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1992	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

267	NULL
,	NULL
No	NULL
.	NULL

5	NULL
,	NULL
Issue	NULL
of	NULL
February	NULL
15	NULL
,	NULL
pp	NULL
.	NULL

3044-3051	NULL
,	NULL
1992	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

Structure	NULL
Function	NULL
Analysis	NULL
of	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
April	NULL
5	NULL
,	NULL
1991	NULL
)	NULL
Roger	NULL
Bouillon	NULL
}	NULL
{	NULL
,	NULL
Katrien	NULL
Allewaert	NULL
}	NULL
#	NULL
,	NULL
Johannes	NULL
P.	NULL
T.	NULL
M.	NULL
van	NULL
Biauw-Keng	NULL
Tant	NULL
,	NULL
Da	NULL
Zhen	NULL
Xiangt	NULL
,	NULL
Pierre	NULL
De	NULL
Clercq	NULL
]	NULL
,	NULL
Maurits	NULL
Vandewalle||	NULL
,	NULL
Huibert	NULL
A.	NULL
P.	NULL
Pols	NULL
,	NULL
Martine	NULL
P.	NULL
Bos**	NULL
,	NULL
Hugo	NULL
Van	NULL
Baelent	NULL
,	NULL
and	NULL
Jan	NULL
C.	NULL
Birkenhager	NULL
!	NULL

From	NULL
the	NULL
{	NULL
Laboratorium	NULL
voor	NULL
Experimentele	NULL
Geneeskunde	NULL
en	NULL
Endocrinologie	NULL
,	NULL
Katholieke	NULL
Universiteit	NULL
Leuven	NULL
,	NULL
Onderwijs	NULL
en	NULL
Navorsing	NULL
,	NULL
Gasthuisberg	NULL
,	NULL
Leuven	NULL
,	NULL
Belgium	NULL
,	NULL
the	NULL
||	NULL
Laboratory	NULL
of	NULL
Organic	NULL
Chemistry	NULL
,	NULL
Rijksuniversiteit	NULL
,	NULL
Ghent	NULL
,	NULL
Belgium	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
III	NULL
,	NULL
Erasmus	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Rotterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
,	NULL
and	NULL
the	NULL
**Laboratory	NULL
for	NULL
Cell	NULL
Biology	NULL
and	NULL
Histology	NULL
,	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
Analogs	NULL
of	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
1a,25-	NULL
(	NULL
0OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
with	NULL
substitutions	NULL
on	NULL
C-11	NULL
were	NULL
synthesized	NULL
.	NULL

Small	NULL
apolar	NULL
substitutions	NULL
(	NULL
11a-methyl	NULL
,	NULL
11a-fluoro-methyl	NULL
)	NULL
did	NULL
not	NULL
markedly	NULL
decrease	NULL
the	NULL
affinity	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
,	NULL
but	NULL
larger	NULL
(	NULL
11a-chloromethyl	NULL
or	NULL
11a-	NULL
or	NULL
or	NULL
more	NULL
polar	NULL
substitutions	NULL
(	NULL
11a	NULL
«	NULL
-hydroxymethyl	NULL
,	NULL
11a	NULL
«	NULL
-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
)	NULL
decreased	NULL
the	NULL
affinity	NULL
to	NULL
less	NULL
than	NULL
5	NULL
%	NULL
of	NULL
that	NULL
of	NULL
1	NULL
«	NULL
,25-O0H	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Their	NULL
affinity	NULL
for	NULL
the	NULL
vitamin	NULL
D-binding	NULL
protein	NULL
,	NULL
however	NULL
,	NULL
increased	NULL
up	NULL
to	NULL
4-fold	NULL
.	NULL

The	NULL
biological	NULL
activity	NULL
of	NULL
1l1l1a-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
closely	NULL
resembled	NULL
that	NULL
of	NULL
the	NULL
natural	NULL
hormone	NULL
on	NULL
normal	NULL
and	NULL
leukemic	NULL
cell	NULL
proliferation	NULL
and	NULL
bone	NULL
resorption	NULL
,	NULL
whereas	NULL
its	NULL
in	NULL
vivo	NULL
effect	NULL
on	NULL
calcium	NULL
metabolism	NULL
of	NULL
the	NULL
rachitic	NULL
chick	NULL
was	NULL
about	NULL
50	NULL
%	NULL
of	NULL
that	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
.	NULL

The	NULL
11	NULL
@	NULL
-methyl	NULL
analog	NULL
had	NULL
a	NULL
>	NULL
10-fold	NULL
lower	NULL
activity	NULL
.	NULL

The	NULL
differentiating	NULL
effects	NULL
of	NULL
the	NULL
other	NULL
C-11	NULL
analogs	NULL
on	NULL
human	NULL
promyeloid	NULL
leukemia	NULL
cells	NULL
(	NULL
HL-60	NULL
)	NULL
agreed	NULL
well	NULL
with	NULL
their	NULL
bone-resorbing	NULL
activity	NULL
and	NULL
receptor	NULL
affinity	NULL
,	NULL
but	NULL
they	NULL
demonstrated	NULL
lower	NULL
calcemic	NULL
effects	NULL
in	NULL
vivo	NULL
.	NULL

Large	NULL
or	NULL
polar	NULL
substitutions	NULL
on	NULL
C-11	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
thus	NULL
impair	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
but	NULL
increase	NULL
the	NULL
affinity	NULL
to	NULL
vitamin	NULL
D-binding	NULL
protein	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
many	NULL
C-11-substituted	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
on	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
exceeded	NULL
their	NULL
activity	NULL
on	NULL
calcium	NULL
metabolism	NULL
.	NULL

Vitamin	NULL
D	NULL
is	NULL
metabolized	NULL
into	NULL
a	NULL
large	NULL
number	NULL
of	NULL
metabo-lites	NULL
,	NULL
but	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
'	NULL
is	NULL
the	NULL
major	NULL
hormonal	NULL
form	NULL
of	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Belgian	NULL
Fonds	NULL
voor	NULL
Geneeskun-dig	NULL
Wetenschappelijk	NULL
Onderzoek	NULL
FGWO	NULL
3.0044.89	NULL
(	NULL
to	NULL
R.	NULL
B.	NULL
and	NULL
H.	NULL
V	NULL
.	NULL

B	NULL
.	NULL
)	NULL

and	NULL
by	NULL
the	NULL
Belgian	NULL
Nationaal	NULL
Fonds	NULL
voor	NULL
Wetenschappelijk	NULL
Onderzoek	NULL
and	NULL
Ministry	NULL
for	NULL
``	NULL
Wetenschapsbeleid	NULL
``	NULL
(	NULL
to	NULL
P.	NULL
D.	NULL
C.	NULL
and	NULL
M.	NULL
V.	NULL
)	NULL
.	NULL

Presented	NULL
in	NULL
part	NULL
in	NULL
abstract	NULL
form	NULL
at	NULL
the	NULL
combined	NULL
meeting	NULL
of	NULL
the	NULL
International	NULL
Conference	NULL
on	NULL
Calcium	NULL
Regulating	NULL
Hormones	NULL
and	NULL
the	NULL
American	NULL
Society	NULL
for	NULL
Bone	NULL
Mineral	NULL
Research	NULL
,	NULL
September	NULL
1989	NULL
,	NULL
Montreal	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
LEGENDO	NULL
,	NULL
Onderwijs	NULL
en	NULL
Navorsing	NULL
,	NULL
Gasthuisberg	NULL
,	NULL
B-3000	NULL
Leuven	NULL
,	NULL
Belgium	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
32-16-215971	NULL
;	NULL
Fax	NULL
:	NULL
32-16-215991	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
,	NULL
1	NULL
«	NULL
-25-dihydroxyvi-tamin	NULL
D	NULL
;	NULL
;	NULL
25-OH-Ds	NULL
;	NULL
,	NULL
25-hydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
DBP	NULL
,	NULL
vitamin	NULL
D-binding	NULL
protein	NULL
from	NULL
human	NULL
rat	NULL
or	NULL
chick	NULL
serum	NULL
also	NULL
known	NULL
as	NULL
group-specific	NULL
component	NULL
;	NULL
PBMC	NULL
,	NULL
mixed	NULL
mononuclear	NULL
cells	NULL
isolated	NULL
from	NULL
normal	NULL
peripheral	NULL
human	NULL
blood	NULL
;	NULL
calbindin	NULL
D-28K	NULL
,	NULL
vitamin	NULL
D-dependent	NULL
cal-cium-binding	NULL
protein	NULL
;	NULL
NBT	NULL
,	NULL
4-nitro	NULL
blue	NULL
tetrazolium	NULL
.	NULL

vitamin	NULL
D	NULL
that	NULL
binds	NULL
to	NULL
specific	NULL
receptors	NULL
with	NULL
high	NULL
affinity	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

These	NULL
receptors	NULL
are	NULL
not	NULL
only	NULL
present	NULL
in	NULL
the	NULL
classical	NULL
target	NULL
tissues	NULL
for	NULL
vitamin	NULL
D	NULL
(	NULL
intestine	NULL
and	NULL
bone	NULL
)	NULL
but	NULL
also	NULL
in	NULL
many	NULL
other	NULL
cells	NULL
and	NULL
organs	NULL
,	NULL
especially	NULL
those	NULL
with	NULL
a	NULL
calcium	NULL
transport	NULL
function	NULL
(	NULL
e.g	NULL
.	NULL

placenta	NULL
)	NULL
or	NULL
with	NULL
a	NULL
calcium-dependent	NULL
hormonal	NULL
secretion	NULL
(	NULL
e.g	NULL
.	NULL

endocrine	NULL
pancreas	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
vitamin	NULL
D	NULL
hormone	NULL
modifies	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
both	NULL
normal	NULL
and	NULL
malignant	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

This	NULL
new	NULL
knowledge	NULL
opened	NULL
the	NULL
search	NULL
for	NULL
vitamin	NULL
D	NULL
analogs	NULL
with	NULL
more	NULL
specific	NULL
actions	NULL
on	NULL
one	NULL
of	NULL
these	NULL
target	NULL
tissues	NULL
with	NULL
the	NULL
aim	NULL
of	NULL
specific	NULL
therapeutic	NULL
intervention	NULL
(	NULL
e.g	NULL
.	NULL

for	NULL
immune	NULL
disorders	NULL
,	NULL
cancer	NULL
control	NULL
,	NULL
psoriasis	NULL
,	NULL
or	NULL
osteoporosis	NULL
)	NULL
.	NULL

Many	NULL
other	NULL
steroid	NULL
hormones	NULL
have	NULL
natural	NULL
hydroxylations	NULL
in	NULL
the	NULL
C-ring	NULL
(	NULL
e.g	NULL
.	NULL

corti-sol	NULL
)	NULL
,	NULL
or	NULL
C-ring	NULL
analogs	NULL
have	NULL
important	NULL
agonist	NULL
or	NULL
antagonist	NULL
effects	NULL
(	NULL
e.g	NULL
.	NULL

RU	NULL
38486	NULL
with	NULL
antiprogesterone	NULL
and	NULL
antigluco-corticoid	NULL
effects	NULL
(	NULL
6	NULL
)	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
C-ring	NULL
of	NULL
the	NULL
secosteroid	NULL
structure	NULL
of	NULL
vitamin	NULL
D	NULL
in	NULL
the	NULL
binding	NULL
to	NULL
or	NULL
activation	NULL
of	NULL
the	NULL
natural	NULL
vitamin	NULL
D-binding	NULL
proteins	NULL
was	NULL
not	NULL
yet	NULL
fully	NULL
explored	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
synthesized	NULL
a	NULL
series	NULL
of	NULL
analogs	NULL
of	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
with	NULL
modifications	NULL
of	NULL
the	NULL
C-ring	NULL
at	NULL
C-11	NULL
.	NULL

These	NULL
analogs	NULL
retain	NULL
or	NULL
increase	NULL
their	NULL
binding	NULL
properties	NULL
for	NULL
the	NULL
serum	NULL
vitamin	NULL
D-binding	NULL
protein	NULL
(	NULL
DBP	NULL
)	NULL
,	NULL
whereas	NULL
large	NULL
or	NULL
polar	NULL
substitutions	NULL
decrease	NULL
the	NULL
receptor	NULL
binding	NULL
and	NULL
biological	NULL
activity	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Materials	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
M.	NULL
Uskokovic	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
25-O0H-D	NULL
;	NULL
and	NULL
[	NULL
°H	NULL
]	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
obtained	NULL
from	NULL
Amersham	NULL
(	NULL
Buckinghamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
at	NULL
specific	NULL
activities	NULL
of	NULL
160	NULL
and	NULL
180	NULL
Ci/mmol	NULL
,	NULL
respectively	NULL
.	NULL

[	NULL
methyl-*H	NULL
]	NULL
Thymi-dine	NULL
(	NULL
2	NULL
Ci/mmol	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
the	NULL
same	NULL
company	NULL
.	NULL

Culture	NULL
media	NULL
were	NULL
purchased	NULL
from	NULL
GIBCO	NULL
(	NULL
Roskilde	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

Penicillin	NULL
and	NULL
streptomycin	NULL
were	NULL
from	NULL
Boehringer	NULL
(	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
4-nitro	NULL
blue	NULL
tetrazolium	NULL
(	NULL
NBT	NULL
)	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

Phytohemagglutinin	NULL
came	NULL
from	NULL
Welcome	NULL
(	NULL
Dartford	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Nonspecific	NULL
acid	NULL
esterase	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
cyto-chemical	NULL
assay	NULL
for	NULL
a-naphthyl	NULL
acetate	NULL
esterase	NULL
using	NULL
Sigma	NULL
kit	NULL
90	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Rat	NULL
,	NULL
chick	NULL
,	NULL
and	NULL
human	NULL
serum	NULL
vitamin	NULL
D	NULL
binding	NULL
protein	NULL
(	NULL
hDBP	NULL
)	NULL
and	NULL
hDBP	NULL
-free	NULL
serum	NULL
were	NULL
prepared	NULL
by	NULL
affinity	NULL
chromatog-raphy	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Methods	NULL
Synthesis	NULL
of	NULL
C-11-substituted	NULL
18,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
Analogs-All	NULL
analogs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
obtained	NULL
by	NULL
total	NULL
synthesis	NULL
.	NULL

The	NULL
method	NULL
rests	NULL
on	NULL
the	NULL
Horner	NULL
coupling	NULL
(	NULL
10	NULL
)	NULL
of	NULL
the	NULL
A-ring	NULL
with	NULL
the	NULL
appropriate	NULL
CD-ring	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
;	NULL
skeleton	NULL
,	NULL
both	NULL
in	NULL
the	NULL
required	NULL
enantiomeric	NULL
form	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
practice	NULL
,	NULL
ketones	NULL
1b-1k	NULL
,	NULL
possessing	NULL
the	NULL
various	NULL
substituents	NULL
at	NULL
C-11	NULL
,	NULL
under	NULL
protected	NULL
form	NULL
if	NULL
necessary	NULL
(	NULL
see	NULL
1d	NULL
,	NULL
1h	NULL
,	NULL
and	NULL
1i	NULL
)	NULL
,	NULL
were	NULL
condensed	NULL
with	NULL
the	NULL
lithium	NULL
salt	NULL
of	NULL
the	NULL
protected	NULL
phosphine	NULL
oxide	NULL
2	NULL
,	NULL
yielding	NULL
the	NULL
corresponding	NULL
trienes	NULL
3	NULL
.	NULL

Consistently	NULL
3044	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
ore	NULL
Rr	NULL
,	NULL
oce	NULL
R	NULL
;	NULL
.	NULL

H	NULL
protective	NULL
group	NULL
coupling	NULL
removal	NULL
l	NULL
R	NULL
TBDMSO®	NULL
``	NULL
otBoms	NULL
ho	NULL
TBDMSO®	NULL
``	NULL
3	NULL
~	NULL
``	NULL
!	NULL

NOTBOMS	NULL
2	NULL
3	NULL
Ri	NULL
R2	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Basic	NULL
strategy	NULL
used	NULL
for	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
»	NULL
D	NULL
synthesis	NULL
of	NULL
C-11-substituted	NULL
ana-	NULL
a	NULL
H	NULL
i	NULL
a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
logs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

b	NULL
-CH3	NULL
H	NULL
11a-methyl-10,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
c	NULL
H	NULL
-CH3	NULL
118-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
d	NULL
-CH	NULL
;	NULL
0OTBDMS	NULL
H	NULL
11a-hydroxymethyl-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
e	NULL
-CHaF	NULL
H	NULL
11a-fluoromethy1-10,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
f	NULL
-CH2CH3	NULL
H	NULL
11a-ethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
£	NULL
-CH=CH2	NULL
H	NULL
11e-vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
h	NULL
-CH2CH2OTHP	NULL
H	NULL
110-	NULL
(	NULL
2-hydroxyethy1	NULL
)	NULL
-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D	NULL
i	NULL
H	NULL
~-CH2CH	NULL
,	NULL
OTHP	NULL
118-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-10,25-	NULL
(	NULL
OH	NULL
)	NULL
pD	NULL
j	NULL
~Ph	NULL
H	NULL
11a-phenyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
k	NULL
H	NULL
-Ph	NULL
118-phenyl-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
OTBDMS	NULL
=	NULL
-	NULL
OSi	NULL
(	NULL
Me	NULL
)	NULL
at.Bu	NULL
OEE	NULL
=	NULL
OCH	NULL
(	NULL
Me	NULL
)	NULL
OEt	NULL
10	NULL
,	NULL
k	NULL
,	NULL
}	NULL
8	NULL
166	NULL
,	NULL
k	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Synopsis	NULL
of	NULL
the	NULL
synthetic	NULL
pathways	NULL
used	NULL
for	NULL
the	NULL
synthesis	NULL
of	NULL
C-11-substituted	NULL
analogs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

The	NULL
nomenclature	NULL
is	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1.	NULL
lower	NULL
yields	NULL
(	NULL
~20-40	NULL
%	NULL
)	NULL
were	NULL
observed	NULL
when	NULL
coupling	NULL
derivatives	NULL
that	NULL
possess	NULL
the	NULL
B-oriented	NULL
substituent	NULL
at	NULL
C-11	NULL
,	NULL
as	NULL
in	NULL
le	NULL
,	NULL
1i	NULL
,	NULL
and	NULL
1k	NULL
.	NULL

At	NULL
the	NULL
stage	NULL
of	NULL
the	NULL
coupling	NULL
reaction	NULL
,	NULL
all	NULL
hydroxyl	NULL
groups	NULL
(	NULL
i.e	NULL
.	NULL

at	NULL
C-1	NULL
,	NULL
C-3	NULL
,	NULL
and	NULL
C-25	NULL
)	NULL
needed	NULL
to	NULL
be	NULL
protected	NULL
.	NULL

Removal	NULL
of	NULL
these	NULL
protective	NULL
groups	NULL
in	NULL
3	NULL
under	NULL
acidic	NULL
conditions	NULL
was	NULL
the	NULL
final	NULL
step	NULL
in	NULL
the	NULL
synthesis	NULL
and	NULL
led	NULL
to	NULL
the	NULL
analogs	NULL
listed	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
protected	NULL
phosphine	NULL
oxide	NULL
2	NULL
was	NULL
obtained	NULL
following	NULL
a	NULL
known	NULL
method	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
C-11	NULL
substituent	NULL
,	NULL
the	NULL
various	NULL
derivatives	NULL
1b-1k	NULL
were	NULL
synthesized	NULL
using	NULL
different	NULL
methods	NULL
.	NULL

These	NULL
are	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
briefly	NULL
described	NULL
below	NULL
.	NULL

Full	NULL
synthetic	NULL
details	NULL
will	NULL
be	NULL
described	NULL
elsewhere	NULL
.	NULL

The	NULL
synthesis	NULL
of	NULL
derivatives	NULL
1b	NULL
,	NULL
1f	NULL
,	NULL
1g	NULL
,	NULL
and	NULL
1j	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
.	NULL

The	NULL
appropriately	NULL
functionalized	NULL
CD-ring	NULL
skeleton	NULL
was	NULL
obtained	NULL
OTHP=	NULL
mfoj	NULL
by	NULL
oxidative	NULL
fission	NULL
of	NULL
the	NULL
triene	NULL
system	NULL
and	NULL
of	NULL
the	NULL
22,23-double	NULL
bond	NULL
in	NULL
vitamin	NULL
D	NULL
;	NULL
,	NULL
followed	NULL
by	NULL
reduction	NULL
to	NULL
Inhoffen-Lythgoe	NULL
diol	NULL
4	NULL
(	NULL
12	NULL
)	NULL
.	NULL

After	NULL
selective	NULL
activation	NULL
of	NULL
the	NULL
primary	NULL
alcohol	NULL
in	NULL
4	NULL
,	NULL
the	NULL
side	NULL
chain	NULL
at	NULL
C-22	NULL
was	NULL
completed	NULL
,	NULL
bearing	NULL
the	NULL
25-hydroxyl	NULL
under	NULL
protected	NULL
form	NULL
(	NULL
13	NULL
)	NULL
.	NULL

After	NULL
oxidation	NULL
of	NULL
the	NULL
alcohol	NULL
in	NULL
5	NULL
to	NULL
the	NULL
corresponding	NULL
ketone	NULL
,	NULL
a	NULL
conjugated	NULL
double	NULL
bond	NULL
was	NULL
introduced	NULL
following	NULL
standard	NULL
methodology	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
enone	NULL
6	NULL
then	NULL
served	NULL
as	NULL
a	NULL
substrate	NULL
for	NULL
the	NULL
introduction	NULL
at	NULL
C-11	NULL
of	NULL
the	NULL
methyl	NULL
(	NULL
1b	NULL
)	NULL
,	NULL
ethyl	NULL
(	NULL
1f	NULL
)	NULL
,	NULL
vinyl	NULL
(	NULL
1g	NULL
)	NULL
,	NULL
and	NULL
phenyl	NULL
(	NULL
1j	NULL
)	NULL
substituents	NULL
using	NULL
the	NULL
appropriate	NULL
organocopper	NULL
reagents	NULL
(	NULL
16-18	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
the	NULL
vinyl-substituted	NULL
derivative	NULL
1g	NULL
was	NULL
the	NULL
precursor	NULL
for	NULL
1d	NULL
and	NULL
le	NULL
and	NULL
may	NULL
also	NULL
serve	NULL
to	NULL
obtain	NULL
1h	NULL
.	NULL

The	NULL
oxidative	NULL
fission	NULL
of	NULL
the	NULL
vinyl	NULL
bond	NULL
,	NULL
followed	NULL
by	NULL
reduction	NULL
,	NULL
leads	NULL
to	NULL
diol	NULL
7	NULL
.	NULL

After	NULL
selective	NULL
protection	NULL
of	NULL
the	NULL
primary	NULL
alcohol	NULL
,	NULL
further	NULL
oxidation	NULL
led	NULL
to	NULL
ketone	NULL
1d	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
selective	NULL
activation	NULL
of	NULL
the	NULL
primary	NULL
alcohol	NULL
allowed	NULL
for	NULL
the	NULL
further	NULL
introduction	NULL
of	NULL
a	NULL
fluorine	NULL
substituent	NULL
(	NULL
19	NULL
)	NULL
;	NULL
analogous	NULL
oxidation	NULL
here	NULL
resulted	NULL
in	NULL
ketone	NULL
le	NULL
.	NULL

A	NULL
nondestructive	NULL
oxidation	NULL
of	NULL
the	NULL
vinyl	NULL
double	NULL
bond	NULL
in	NULL
1g	NULL
using	NULL
9-borabicyclononane/hydrogen	NULL
peroxide	NULL
opened	NULL
the	NULL
way	NULL
to	NULL
the	NULL
2-hy-droxyethyl-substituted	NULL
derivative	NULL
1h	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Derivatives	NULL
possessing	NULL
a	NULL
G-oriented	NULL
substituent	NULL
at	NULL
C-11	NULL
,	NULL
ie	NULL
.	NULL

1¢	NULL
,	NULL
1i	NULL
,	NULL
and	NULL
1k	NULL
,	NULL
were	NULL
obtained	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
.	NULL

Starting	NULL
from	NULL
the	NULL
already	NULL
described	NULL
1b	NULL
,	NULL
1h	NULL
,	NULL
and	NULL
1	NULL
}	NULL
,	NULL
a	NULL
double	NULL
bond	NULL
was	NULL
first	NULL
introduced	NULL
as	NULL
in	NULL
8	NULL
.	NULL

Subsequent	NULL
catalytic	NULL
hydrogenation	NULL
then	NULL
afforded	NULL
the	NULL
required	NULL
derivatives	NULL
with	NULL
epimeric	NULL
configuration	NULL
at	NULL
C-11	NULL
.	NULL

Cells	NULL
and	NULL
Animals-The	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL-60	NULL
)	NULL
and	NULL
UMR	NULL
106	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Tissue	NULL
Culture	NULL
Company	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
T.	NULL
J.	NULL
Martin	NULL
(	NULL
Melbourne	NULL
,	NULL
Australia	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Peripheral	NULL
blood	NULL
mixed	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
buffy	NULL
coats	NULL
of	NULL
human	NULL
blood	NULL
obtained	NULL
from	NULL
the	NULL
Belgian	NULL
Red	NULL
Cross	NULL
.	NULL

Vitamin	NULL
D-deficient	NULL
chicks	NULL
were	NULL
reared	NULL
on	NULL
a	NULL
vitamin	NULL
D-deficient	NULL
diet	NULL
(	NULL
1	NULL
%	NULL
calcium	NULL
,	NULL
1	NULL
%	NULL
phosphorus	NULL
,	NULL
Hope	NULL
farms	NULL
,	NULL
Woerden	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
and	NULL
housed	NULL
in	NULL
a	NULL
windowless	NULL
room	NULL
.	NULL

After	NULL
3	NULL
weeks	NULL
,	NULL
they	NULL
received	NULL
a	NULL
daily	NULL
intramuscular	NULL
injection	NULL
for	NULL
10	NULL
days	NULL
with	NULL
or	NULL
its	NULL
analogs	NULL
solubilized	NULL
in	NULL
polyethylene	NULL
glycol	NULL
.	NULL

Serum	NULL
,	NULL
bone	NULL
,	NULL
and	NULL
duodenal	NULL
mucosa	NULL
were	NULL
then	NULL
collected	NULL
under	NULL
Nembutal	NULL
anesthesia	NULL
.	NULL

Calcium	NULL
was	NULL
measured	NULL
by	NULL
atomic	NULL
absorptiom-etry	NULL
in	NULL
serum	NULL
and	NULL
ashed	NULL
bone	NULL
.	NULL

Serum	NULL
osteocalcin	NULL
and	NULL
duodenal	NULL
calbindin	NULL
D-28K	NULL
were	NULL
measured	NULL
by	NULL
radioimmunoassay	NULL
using	NULL
specific	NULL
anti-chick	NULL
antisera	NULL
raised	NULL
against	NULL
these	NULL
chick	NULL
proteins	NULL
.	NULL

3046	NULL
Binding	NULL
Studies-Binding	NULL
of	NULL
vitamin	NULL
D	NULL
metabolites	NULL
and	NULL
analogs	NULL
to	NULL
hDBP	NULL
was	NULL
performed	NULL
at	NULL
4	NULL
°C	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
21	NULL
)	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
or	NULL
its	NULL
analogs	NULL
were	NULL
added	NULL
in	NULL
5	NULL
ul	NULL
of	NULL
ethanol	NULL
into	NULL
glass	NULL
tubes	NULL
and	NULL
incubated	NULL
with	NULL
hDBP	NULL
(	NULL
0.18	NULL
LM	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
1	NULL
ml	NULL
(	NULL
0.01	NULL
M	NULL
Tris-HCl	NULL
,	NULL
0.154	NULL
m	NULL
NaCl	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
for	NULL
3	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Phase	NULL
separation	NULL
was	NULL
then	NULL
obtained	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
0.5	NULL
ml	NULL
of	NULL
cold	NULL
dextran-coated	NULL
charcoal	NULL
.	NULL

The	NULL
binding	NULL
to	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
was	NULL
estimated	NULL
in	NULL
either	NULL
rat	NULL
duodenal	NULL
mucosa	NULL
or	NULL
in	NULL
rat	NULL
osteoblastic	NULL
cells	NULL
(	NULL
UMR	NULL
106	NULL
cells	NULL
)	NULL
.	NULL

Duodenal	NULL
mucosa	NULL
from	NULL
normal	NULL
Wistar	NULL
rats	NULL
was	NULL
sonicated	NULL
in	NULL
4	NULL
volumes	NULL
of	NULL
buffer	NULL
(	NULL
0.05	NULL
M	NULL
Tris-HCl	NULL
,	NULL
0.5	NULL
M	NULL
KCl	NULL
,	NULL
5	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
10	NULL
mM	NULL
Na	NULL
;	NULL
MoO	NULL
,	NULL
,	NULL
and	NULL
1.5	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
7.5	NULL
)	NULL
.	NULL

The	NULL
high	NULL
speed	NULL
supernatant	NULL
was	NULL
then	NULL
incubated	NULL
with	NULL
0.2	NULL
nm	NULL
[	NULL
°H	NULL
]	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
14,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
or	NULL
its	NULL
analogs	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
0.3	NULL
ml	NULL
for	NULL
15	NULL
min	NULL
at	NULL
25	NULL
°C	NULL
followed	NULL
by	NULL
5	NULL
min	NULL
at	NULL
0	NULL
°C	NULL
.	NULL

Phase	NULL
separation	NULL
was	NULL
then	NULL
obtained	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
cold	NULL
dextran-coated	NULL
charcoal	NULL
.	NULL

The	NULL
osteoblast	NULL
homogenate	NULL
was	NULL
obtained	NULL
from	NULL
UMR	NULL
106	NULL
cells	NULL
grown	NULL
from	NULL
the	NULL
last	NULL
24	NULL
h	NULL
in	NULL
a-minimum	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
charcoal-treated	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
trypsinized	NULL
,	NULL
and	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
extracted	NULL
on	NULL
ice	NULL
in	NULL
a	NULL
hypertonic	NULL
buffer	NULL
as	NULL
was	NULL
done	NULL
for	NULL
the	NULL
duodenal	NULL
mucosa	NULL
,	NULL
and	NULL
the	NULL
receptor	NULL
binding	NULL
was	NULL
measured	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Culture	NULL
Conditions	NULL
for	NULL
Mitogen-induced	NULL
Proliferation	NULL
of	NULL
Peripheral	NULL
Blood	NULL
Mononuclear	NULL
Cells-PBMC	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
buffy	NULL
coat	NULL
of	NULL
blood	NULL
donors	NULL
by	NULL
centrifugation	NULL
of	NULL
heparinized	NULL
venous	NULL
blood	NULL
on	NULL
Ficoll-Paque	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

The	NULL
culture	NULL
conditions	NULL
were	NULL
identical	NULL
with	NULL
those	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
,	NULL
except	NULL
that	NULL
the	NULL
culture	NULL
medium	NULL
in	NULL
the	NULL
present	NULL
study	NULL
was	NULL
RPMI	NULL
1640	NULL
.	NULL

Culture	NULL
Conditions	NULL
for	NULL
HL-60	NULL
Cells-HL-60	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
1.2	NULL
X	NULL
10°	NULL
cells/ml	NULL
,	NULL
and	NULL
or	NULL
its	NULL
analogs	NULL
were	NULL
added	NULL
in	NULL
ethanol	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
<	NULL
0.2	NULL
%	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
(	NULL
Boehringer	NULL
)	NULL
.	NULL

After	NULL
4	NULL
days	NULL
of	NULL
culture	NULL
in	NULL
a	NULL
humified	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
air	NULL
at	NULL
37	NULL
°C	NULL
,	NULL
the	NULL
dishes	NULL
were	NULL
shaken	NULL
to	NULL
lose	NULL
any	NULL
adherent	NULL
cells	NULL
,	NULL
and	NULL
all	NULL
cells	NULL
were	NULL
then	NULL
assayed	NULL
for	NULL
maturation	NULL
by	NULL
NBT	NULL
reduction	NULL
assay	NULL
and	NULL
for	NULL
proliferation	NULL
by	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

NBT	NULL
Reduction	NULL
Assay-Superoxide	NULL
production	NULL
was	NULL
assayed	NULL
by	NULL
NBT-reducing	NULL
activity	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

HL-60	NULL
cells	NULL
at	NULL
1.5	NULL
x	NULL
10°	NULL
cells/ml	NULL
were	NULL
mixed	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
freshly	NULL
prepared	NULL
solution	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
and	NULL
NBT	NULL
(	NULL
2	NULL
mg/ml	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
containing	NULL
black	NULL
formazan	NULL
deposits	NULL
was	NULL
determined	NULL
using	NULL
a	NULL
hemacy-tometer	NULL
.	NULL

Bone	NULL
Resorption	NULL
Assay-Bone	NULL
resorption	NULL
was	NULL
measured	NULL
as	NULL
the	NULL
release	NULL
of	NULL
previously	NULL
incorporated	NULL
Ca	NULL
from	NULL
17-day-old	NULL
fetal	NULL
radii	NULL
and	NULL
ulnae	NULL
after	NULL
3	NULL
and	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
as	NULL
described	NULL
in	NULL
the	NULL
fetal	NULL
rat	NULL
limb	NULL
explant	NULL
assay	NULL
of	NULL
Raisz	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
radii	NULL
and	NULL
ulnae	NULL
were	NULL
cultured	NULL
in	NULL
BGJ	NULL
,	NULL
medium	NULL
with	NULL
2	NULL
%	NULL
charcoal-treated	NULL
fetal	NULL
calf	NULL
serum	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
40	NULL
%	NULL
O	NULL
;	NULL
,	NULL
55	NULL
%	NULL
N	NULL
;	NULL
,	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

To	NULL
reduce	NULL
free	NULL
exchangeable	NULL
calcium	NULL
,	NULL
the	NULL
limb	NULL
explants	NULL
were	NULL
precultured	NULL
for	NULL
24	NULL
h.	NULL
The	NULL
medium	NULL
was	NULL
then	NULL
replaced	NULL
by	NULL
control	NULL
medium	NULL
or	NULL
medium	NULL
containing	NULL
14	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
one	NULL
of	NULL
the	NULL
analogs	NULL
.	NULL

After	NULL
3	NULL
days	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
replaced	NULL
by	NULL
fresh	NULL
medium	NULL
of	NULL
the	NULL
same	NULL
composition	NULL
.	NULL

The	NULL
Ca	NULL
content	NULL
of	NULL
the	NULL
medium	NULL
at	NULL
3	NULL
and	NULL
6	NULL
days	NULL
and	NULL
of	NULL
the	NULL
5	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
extracts	NULL
of	NULL
the	NULL
bones	NULL
were	NULL
measured	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
and	NULL
used	NULL
to	NULL
calculate	NULL
the	NULL
total	NULL
``	NULL
Ca	NULL
content	NULL
and	NULL
the	NULL
cumulative	NULL
percentage	NULL
of	NULL
``	NULL
``	NULL
Ca	NULL
released	NULL
.	NULL

Measurement	NULL
of	NULL
25-O0H-D	NULL
;	NULL
-24-hydroxylase	NULL
Activity-UMR	NULL
106	NULL
cells	NULL
were	NULL
cultured	NULL
as	NULL
described	NULL
above	NULL
.	NULL

After	NULL
the	NULL
second	NULL
culture	NULL
period	NULL
of	NULL
24	NULL
h	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
changed	NULL
to	NULL
serum-free	NULL
«	NULL
-minimum	NULL
Eagle	NULL
's	NULL
medium	NULL
containing	NULL
0.1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
one	NULL
of	NULL
the	NULL
analogs	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
for	NULL
2	NULL
h	NULL
with	NULL
a-minimum	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
followed	NULL
by	NULL
an	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
with	NULL
[	NULL
°H	NULL
}	NULL
25-0H-D	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
formation	NULL
of	NULL
24,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
was	NULL
assessed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
25	NULL
)	NULL
.	NULL

RESULTS	NULL
Binding	NULL
Studies-The	NULL
affinity	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
in	NULL
rat	NULL
duodenal	NULL
mucosa	NULL
,	NULL
as	NULL
measured	NULL
at	NULL
4°C	NULL
and	NULL
pH	NULL
7.4	NULL
and	NULL
analyzed	NULL
by	NULL
Scatchard	NULL
plot	NULL
,	NULL
was	NULL
1.4	NULL
*+	NULL
0.8	NULL
x	NULL
10°	NULL
MC	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
»	NULL
=	NULL
10	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
rat	NULL
osteoblast	NULL
sarcoma	NULL
and	NULL
calf	NULL
thymus	NULL
homoge-nates	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
substitution	NULL
of	NULL
C-11	NULL
of	NULL
on	NULL
receptor	NULL
binding	NULL
is	NULL
summarized	NULL
in	NULL
Table	NULL
I	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
and	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
methyl	NULL
or	NULL
fluoromethyl	NULL
group	NULL
on	NULL
C-11	NULL
did	NULL
not	NULL
markedly	NULL
alter	NULL
the	NULL
binding	NULL
properties	NULL
,	NULL
whereas	NULL
l11a-ethyl	NULL
or	NULL
l1a-vinyl	NULL
groups	NULL
caused	NULL
a	NULL
5-10-fold	NULL
decrease	NULL
in	NULL
receptor	NULL
binding	NULL
.	NULL

A	NULL
still	NULL
larger	NULL
(	NULL
phenyl	NULL
)	NULL
or	NULL
more	NULL
polar	NULL
(	NULL
11a-OHCH	NULL
;	NULL
or	NULL
11a-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
)	NULL
group	NULL
further	NULL
decreased	NULL
the	NULL
receptor	NULL
affinity	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
stereochemistry	NULL
of	NULL
the	NULL
substitution	NULL
also	NULL
influenced	NULL
the	NULL
affinity	NULL
,	NULL
but	NULL
the	NULL
effect	NULL
was	NULL
different	NULL
for	NULL
11-methyl	NULL
and	NULL
11-phenyl	NULL
groups	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
14,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
hDBP	NULL
at	NULL
4	NULL
°C	NULL
was	NULL
1.5	NULL
+	NULL
0.2	NULL
X	NULL
10	NULL
``	NULL
M~	NULL
'	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
»	NULL
=	NULL
6	NULL
)	NULL
.	NULL

Apolar	NULL
substitutions	NULL
with	NULL
one	NULL
or	NULL
two	NULL
carbons	NULL
in	NULL
position	NULL
C-11	NULL
increased	NULL
the	NULL
affinity	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
for	NULL
hDBP	NULL
,	NULL
whereas	NULL
even	NULL
large	NULL
polar	NULL
substitutions	NULL
did	NULL
not	NULL
markedly	NULL
decrease	NULL
the	NULL
binding	NULL
to	NULL
hDBP	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
analogs	NULL
with	NULL
the	NULL
highest	NULL
affinity	NULL
for	NULL
hDBP	NULL
were	NULL
1la=vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
3.8-fold	NULL
increase	NULL
in	NULL
affinity	NULL
)	NULL
and	NULL
11a-methyl-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
3.4-fold	NULL
increase	NULL
in	NULL
affinity	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
some	NULL
analogs	NULL
(	NULL
lla-ethyl-	NULL
and	NULL
1l1a-vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
to	NULL
purified	NULL
rat	NULL
and	NULL
chick	NULL
DBP	NULL
also	NULL
indicated	NULL
an	NULL
increased	NULL
affinity	NULL
of	NULL
the	NULL
same	NULL
analogs	NULL
(	NULL
2-4-fold	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
C-11	NULL
Substitution	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
Leucocyte	NULL
Function-The	NULL
proliferation	NULL
of	NULL
phytohemagglutinin-stimu-lated	NULL
mixed	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
its	NULL
analogs	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Only	NULL
11a-methyl-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
retained	NULL
a	NULL
marked	NULL
potency	NULL
both	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
physiological	NULL
amounts	NULL
of	NULL
hDBP	NULL
.	NULL

Of	NULL
all	NULL
the	NULL
other	NULL
C-11-substituted	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
,	NULL
only	NULL
showed	NULL
a	NULL
relative	NULL
potency	NULL
exceeding	NULL
2	NULL
%	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
DBP	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
absolute	NULL
concentration	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
its	NULL
several	NULL
analogs	NULL
necessary	NULL
for	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
proliferation	NULL
varied	NULL
between	NULL
5	NULL
x	NULL
10	NULL
,	NULL
M	NULL
for	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
more	NULL
than	NULL
10°	NULL
M	NULL
for	NULL
ll1a-phenyl-	NULL
and	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
DBP	NULL
always	NULL
decreased	NULL
the	NULL
effect	NULL
of	NULL
1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
its	NULL
analogs	NULL
between	NULL
10-	NULL
and	NULL
100-fold	NULL
,	NULL
but	NULL
the	NULL
rank	NULL
order	NULL
remained	NULL
essentially	NULL
unchanged	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
antiproliferative	NULL
effect	NULL
of	NULL
the	NULL
hemisuccinate	NULL
of	NULL
11a	NULL
«	NULL
-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
was	NULL
markedly	NULL
lower	NULL
than	NULL
its	NULL
nonesterified	NULL
analog	NULL
in	NULL
contrast	NULL
to	NULL
their	NULL
similar	NULL
receptor-binding	NULL
properties	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
was	NULL
markedly	NULL
enhanced	NULL
by	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
all	NULL
the	NULL
11a-	NULL
or	NULL
analogs	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Using	NULL
NBT	NULL
as	NULL
the	NULL
end	NULL
point	NULL
for	NULL
vitamin	NULL
D	NULL
effects	NULL
,	NULL
lla-methyl	NULL
,	NULL
l1a-fluoromethyl	NULL
,	NULL
l1a-vinyl	NULL
,	NULL
and	NULL
1ll1a-ethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
all	NULL
very	NULL
effective	NULL
,	NULL
whereas	NULL
the	NULL
larger	NULL
or	NULL
more	NULL
polar	NULL
analogs	NULL
were	NULL
less	NULL
active	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
analogs	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
nonspecific	NULL
esterase	NULL
activity	NULL
differed	NULL
only	NULL
slightly	NULL
from	NULL
their	NULL
effect	NULL
in	NULL
the	NULL
NBT	NULL
reaction	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
differentiating	NULL
effect	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
on	NULL
HL-60	NULL
cells	NULL
was	NULL
reciprocal	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
this	NULL
steroid	NULL
on	NULL
HL-60	NULL
cell	NULL
proliferation	NULL
as	NULL
measured	NULL
by	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
so	NULL
that	NULL
an	NULL
excellent	NULL
negative	NULL
correlation	NULL
between	NULL
both	NULL
parameters	NULL
was	NULL
observed	NULL
(	NULL
r	NULL
=	NULL
0.9	NULL
;	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
response	NULL
was	NULL
observed	NULL
for	NULL
three	NULL
of	NULL
the	NULL
C-11-substituted	NULL
14a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
analogs	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
dose-response	NULL
curve	NULL
for	NULL
the	NULL
reduction	NULL
of	NULL
HL-60	NULL
cell	NULL
number	NULL
by	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
,	NULL
however	NULL
,	NULL
shifted	NULL
to	NULL
the	NULL
right	NULL
by	NULL
1	NULL
order	NULL
of	NULL
magnitude	NULL
in	NULL
comparison	NULL
with	NULL
the	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
Effect	NULL
of	NULL
C-11	NULL
Substitution	NULL
on	NULL
Bone	NULL
Resorption-The	NULL
release	NULL
of	NULL
*Ca	NULL
from	NULL
prelabeled	NULL
fetal	NULL
mouse	NULL
radii	NULL
and	NULL
ulnae	NULL
after	NULL
3	NULL
and	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Both	NULL
at	NULL
3	NULL
and	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
and	NULL
natural	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
equipotent	NULL
,	NULL
whereas	NULL
11	NULL
«	NULL
-phenyl	NULL
and	NULL
11a-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
much	NULL
less	NULL
active	NULL
in	NULL
mobilizing	NULL
calcium	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
hemisucci-	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
3047	NULL
TABLE	NULL
I	NULL
Biological	NULL
activity	NULL
of	NULL
C-ring	NULL
analogs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
Summary	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
substitution	NULL
of	NULL
C-11	NULL
of	NULL
14,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
on	NULL
receptor	NULL
and	NULL
hDBP	NULL
binding	NULL
,	NULL
HL-60	NULL
differentiation	NULL
,	NULL
PBMC	NULL
proliferation	NULL
,	NULL
bone	NULL
resorption	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
biological	NULL
activity	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
rachitic	NULL
chick	NULL
.	NULL

All	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
activity	NULL
(	NULL
at	NULL
50	NULL
%	NULL
of	NULL
the	NULL
dose	NULL
response	NULL
)	NULL
,	NULL
in	NULL
comparison	NULL
with	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
(	NULL
=	NULL
100	NULL
%	NULL
activity	NULL
)	NULL
.	NULL

Receptor	NULL
binding	NULL
,	NULL
|__	NULL
HL.60	NULL
differ	NULL
ppyc	NULL
3°13	NULL
;	NULL
one	NULL
_	NULL
Biological	NULL
activity	NULL
in	NULL
rachitic	NULL
chick*	NULL
Metabolite/analog	NULL
onc	NULL
:	NULL
entiation	NULL
.	NULL

pro-bindin	NULL
;	NULL
liferation	NULL
aa	NULL
:	NULL
Rat	NULL
duo-	NULL
UMR	NULL
106	NULL
€	NULL
(	NULL
NBT	NULL
)	NULL
3-day	NULL
6-4	NULL
Serum	NULL
-	NULL
Bone	NULL
Serum	NULL
os-	NULL
Calbindin	NULL
denum	NULL
cells	NULL
``	NULL
CY	NULL
©0289	NULL
calcium	NULL
calcium	NULL
teocalcin	NULL
-	NULL
D-28K	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
:	NULL
D	NULL
;	NULL
100°	NULL
100	NULL
100	NULL
``	NULL
100°	NULL
100	NULL
100	NULL
100	NULL
100	NULL
100	NULL
100	NULL
100	NULL
11a-Methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
230	NULL
80	NULL
340	NULL
113	NULL
90	NULL
100	NULL
100	NULL
40	NULL
46	NULL
50	NULL
60	NULL
1183-Methyl-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
37	NULL
86	NULL
19	NULL
1.4	NULL
<	NULL
1	NULL
1	NULL
2	NULL
5	NULL
5	NULL
3	NULL
11a-Hydroxymethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
0.3	NULL
107	NULL
7	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
11a-Fluoromethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
75	NULL
133	NULL
250	NULL
63	NULL
1.3	NULL
45	NULL
-	NULL
30	NULL
6	NULL
35	NULL
10	NULL
30	NULL
11a-Chloromethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
12	NULL
160	NULL
28	NULL
6	NULL
20	NULL
6	NULL
8	NULL
3	NULL
4	NULL
11a-Ethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
9	NULL
11	NULL
272	NULL
43	NULL
2	NULL
14	NULL
8	NULL
2	NULL
3	NULL
6	NULL
3	NULL
11a-Vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
24	NULL
67	NULL
380	NULL
81	NULL
1.3	NULL
70	NULL
170	NULL
_	NULL
<	NULL
l	NULL
7	NULL
3	NULL
9	NULL
<	NULL
0.1	NULL
0.3	NULL
115	NULL
7	NULL
<	NULL
1	NULL
<	NULL
l	NULL
<	NULL
l	NULL
<	NULL
l	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
118-	NULL
(	NULL
2-Hydroxyethyl	NULL
)	NULL
-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
0.2	NULL
40	NULL
5	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
11a-Phenyl-14,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
0.2	NULL
<	NULL
0.1	NULL
_	NULL
200	NULL
<	NULL
3	NULL
<	NULL
1	NULL
<	NULL
l	NULL
<	NULL
l	NULL
<	NULL
l	NULL
<	NULL
1	NULL
<	NULL
1	NULL
<	NULL
1	NULL
5	NULL
150	NULL
7	NULL
2.1	NULL
<	NULL
l	NULL
<	NULL
l	NULL
-	NULL
<	NULL
l	NULL
4	NULL
<	NULL
1	NULL
1	NULL
*	NULL
Bone	NULL
resorption	NULL
was	NULL
estimated	NULL
as	NULL
Ca	NULL
release	NULL
after	NULL
3-	NULL
and	NULL
6-day	NULL
cultures	NULL
(	NULL
for	NULL
details	NULL
see	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

*	NULL
The	NULL
in	NULL
vivo	NULL
biological	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
rachitic	NULL
chicks	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
dose	NULL
response	NULL
curve	NULL
obtained	NULL
with	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

°	NULL
Affinity	NULL
at	NULL
4	NULL
°C	NULL
and	NULL
pH	NULL
7.4	NULL
:	NULL
1.4	NULL
+	NULL
0.8	NULL
x	NULL
10°	NULL
MT	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
10	NULL
)	NULL
.	NULL

*	NULL
Affinity	NULL
at	NULL
4	NULL
°C	NULL
and	NULL
pH	NULL
7.4	NULL
;	NULL
1.5	NULL
+	NULL
0.2	NULL
X	NULL
10	NULL
``	NULL
M~	NULL
'	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
.	NULL

*	NULL
The	NULL
concentration	NULL
of	NULL
14,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
necessary	NULL
for	NULL
half-maximal	NULL
response	NULL
in	NULL
a	NULL
differentiating	NULL
assay	NULL
was	NULL
1.5	NULL
%	NULL
10~°	NULL
M	NULL
(	NULL
see	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

''The	NULL
concentration	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
necessary	NULL
for	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
DBP	NULL
-free	NULL
human	NULL
serum	NULL
was	NULL
10~	NULL
``	NULL
.	NULL

nate	NULL
of	NULL
11a-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
its	NULL
nonesterified	NULL
analog	NULL
during	NULL
either	NULL
the	NULL
3-	NULL
or	NULL
6-day	NULL
culture	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
bone-resorbing	NULL
activity	NULL
of	NULL
l1a-vinyl-	NULL
and	NULL
11a-fluoromethyl-14,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
both	NULL
at	NULL
3	NULL
and	NULL
6	NULL
days	NULL
of	NULL
cultures	NULL
,	NULL
was	NULL
less	NULL
than	NULL
that	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
at	NULL
50	NULL
%	NULL
of	NULL
the	NULL
dose	NULL
response	NULL
curve	NULL
,	NULL
with	NULL
a	NULL
relative	NULL
potency	NULL
close	NULL
to	NULL
the	NULL
effect	NULL
observed	NULL
in	NULL
HL-60	NULL
differentiation	NULL
studies	NULL
.	NULL

The	NULL
maximal	NULL
amount	NULL
of	NULL
calcium	NULL
release	NULL
was	NULL
,	NULL
however	NULL
,	NULL
similar	NULL
for	NULL
all	NULL
vitamin	NULL
D	NULL
analogs	NULL
.	NULL

Effect	NULL
of	NULL
C-11	NULL
Substitution	NULL
on	NULL
25-OH-D	NULL
;	NULL
-24-hydroxylase	NULL
Activity-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
11a-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
were	NULL
equipotent	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
24-hydroxylation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
25-0HD	NULL
;	NULL
,	NULL
whereas	NULL
l1a-phenyl	NULL
and	NULL
11a-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
its	NULL
hemisuccinate	NULL
were	NULL
largely	NULL
inactive	NULL
at	NULL
equimolar	NULL
concentrations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Biological	NULL
Activity	NULL
of	NULL
1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
Analogs	NULL
in	NULL
the	NULL
Rachitic	NULL
Chick	NULL
in	NULL
Vivo-The	NULL
concentrations	NULL
of	NULL
calcium	NULL
in	NULL
serum	NULL
and	NULL
bone	NULL
,	NULL
osteocalcin	NULL
in	NULL
serum	NULL
,	NULL
and	NULL
calbindin	NULL
D-28K	NULL
in	NULL
duodenal	NULL
mucosa	NULL
were	NULL
measured	NULL
after	NULL
10	NULL
days	NULL
of	NULL
treatment	NULL
of	NULL
vitamin	NULL
D-deficient	NULL
chicks	NULL
with	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
or	NULL
its	NULL
C-11-substituted	NULL
analogs	NULL
.	NULL

Among	NULL
the	NULL
analogs	NULL
tested	NULL
,	NULL
ll1a-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
the	NULL
most	NULL
potent	NULL
on	NULL
all	NULL
parameters	NULL
but	NULL
nevertheless	NULL
reached	NULL
only	NULL
50	NULL
%	NULL
of	NULL
the	NULL
potency	NULL
of	NULL
14,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
,	NULL
whereas	NULL
its	NULL
B-isomer	NULL
was	NULL
about	NULL
10	NULL
times	NULL
less	NULL
active	NULL
.	NULL

The	NULL
l1a-fluoromethy	NULL
]	NULL
-	NULL
and	NULL
11a-vinyl	NULL
analogs	NULL
also	NULL
showed	NULL
mild	NULL
agonist	NULL
activity	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Larger	NULL
and/or	NULL
more	NULL
polar	NULL
substitutions	NULL
on	NULL
C-11	NULL
nearly	NULL
totally	NULL
abolished	NULL
the	NULL
biological	NULL
activity	NULL
in	NULL
vivo	NULL
.	NULL

DISCUSSION	NULL
Analogs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
with	NULL
substitutions	NULL
in	NULL
the	NULL
C-ring	NULL
at	NULL
C-11	NULL
are	NULL
of	NULL
special	NULL
interest	NULL
,	NULL
and	NULL
only	NULL
limited	NULL
chemical	NULL
or	NULL
biological	NULL
data	NULL
on	NULL
such	NULL
analogs	NULL
are	NULL
available	NULL
(	NULL
7	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
synthesis	NULL
of	NULL
such	NULL
analogs	NULL
is	NULL
best	NULL
realized	NULL
by	NULL
total	NULL
synthesis	NULL
involving	NULL
classical	NULL
coupling	NULL
of	NULL
A	NULL
and	NULL
CD	NULL
fragments	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
skeleton	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
C-11-substituted	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
to	NULL
the	NULL
rat	NULL
vitamin	NULL
D	NULL
receptor	NULL
was	NULL
markedly	NULL
affected	NULL
by	NULL
the	NULL
size	NULL
,	NULL
polarity	NULL
,	NULL
and	NULL
stereochemistry	NULL
of	NULL
the	NULL
substitution	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Analogs	NULL
with	NULL
a	NULL
single	NULL
carbon	NULL
substitution	NULL
retained	NULL
the	NULL
highest	NULL
affinity	NULL
.	NULL

11a-Methyl-	NULL
and	NULL
retained	NULL
nearly	NULL
the	NULL
affinity	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
the	NULL
rat	NULL
osteoblast	NULL
,	NULL
calf	NULL
thymus	NULL
,	NULL
or	NULL
rat	NULL
duodenal	NULL
receptor	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

116-Methyl	NULL
and	NULL
l1a	NULL
«	NULL
-chloromethyl	NULL
substitutions	NULL
already	NULL
reduced	NULL
the	NULL
affinity	NULL
,	NULL
which	NULL
was	NULL
further	NULL
lost	NULL
by	NULL
introduction	NULL
of	NULL
a	NULL
polar	NULL
substitution	NULL
(	NULL
11	NULL
«	NULL
-hydroxymethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Analogs	NULL
with	NULL
two	NULL
or	NULL
more	NULL
carbons	NULL
on	NULL
C-11	NULL
substitutions	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
all	NULL
had	NULL
decreased	NULL
receptor	NULL
affinity	NULL
,	NULL
but	NULL
again	NULL
,	NULL
the	NULL
more	NULL
polar	NULL
analogs	NULL
had	NULL
the	NULL
lowest	NULL
affinity	NULL
.	NULL

The	NULL
largest	NULL
substitution	NULL
(	NULL
phenyl	NULL
)	NULL
also	NULL
decreased	NULL
the	NULL
receptor	NULL
affinity	NULL
,	NULL
but	NULL
of	NULL
the	NULL
two	NULL
stereoisomers	NULL
,	NULL
the	NULL
3	NULL
analog	NULL
retained	NULL
the	NULL
highest	NULL
affinity	NULL
,	NULL
whereas	NULL
for	NULL
11-methyl	NULL
isomers	NULL
,	NULL
the	NULL
a	NULL
analog	NULL
had	NULL
a	NULL
higher	NULL
affinity	NULL
than	NULL
the	NULL
8	NULL
analog	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
receptor-vitamin	NULL
D	NULL
interaction	NULL
is	NULL
thus	NULL
hindered	NULL
by	NULL
polar	NULL
or	NULL
large	NULL
substitutions	NULL
on	NULL
the	NULL
C-ring	NULL
.	NULL

This	NULL
must	NULL
be	NULL
due	NULL
to	NULL
the	NULL
interaction	NULL
at	NULL
the	NULL
hormone-binding	NULL
site	NULL
of	NULL
the	NULL
receptor	NULL
,	NULL
since	NULL
it	NULL
occurs	NULL
as	NULL
well	NULL
in	NULL
direct	NULL
receptor	NULL
binding	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
and	NULL
in	NULL
experiments	NULL
that	NULL
evaluate	NULL
the	NULL
further	NULL
gene	NULL
activation	NULL
by	NULL
the	NULL
receptor-hormone	NULL
complex	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
proximity	NULL
of	NULL
C-11	NULL
to	NULL
the	NULL
hormone-receptor	NULL
binding	NULL
site	NULL
could	NULL
probably	NULL
be	NULL
exploited	NULL
for	NULL
photoaffinity	NULL
labeling	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
hDBP	NULL
was	NULL
similar	NULL
to	NULL
our	NULL
previous	NULL
observations	NULL
(	NULL
20	NULL
)	NULL
and	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
others	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
effect	NULL
on	NULL
receptor	NULL
binding	NULL
,	NULL
substitutions	NULL
on	NULL
C-11	NULL
did	NULL
not	NULL
decrease	NULL
but	NULL
instead	NULL
increased	NULL
the	NULL
affinity	NULL
for	NULL
hDBP	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
no	NULL
C-11	NULL
analog	NULL
(	NULL
except	NULL
showed	NULL
a	NULL
decreased	NULL
binding	NULL
to	NULL
hDBP	NULL
,	NULL
whereas	NULL
several	NULL
small	NULL
substitutions	NULL
increased	NULL
the	NULL
affinity	NULL
severalfold	NULL
.	NULL

The	NULL
stable	NULL
binding	NULL
to	NULL
hDBP	NULL
was	NULL
also	NULL
confirmed	NULL
in	NULL
in	NULL
vitro	NULL
studies	NULL
on	NULL
the	NULL
effect	NULL
of	NULL
vitamin	NULL
D	NULL
analogs	NULL
on	NULL
lymphocyte	NULL
proliferation	NULL
,	NULL
since	NULL
the	NULL
presence	NULL
of	NULL
hDBP	NULL
decreased	NULL
the	NULL
activity	NULL
of	NULL
all	NULL
the	NULL
analogs	NULL
3048	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
affinity	NULL
of	NULL
C-11-substituted	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
was	NULL
also	NULL
observed	NULL
for	NULL
rat	NULL
and	NULL
chick	NULL
DBP	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
C-11	NULL
analogs	NULL
of	NULL
25-OHD	NULL
were	NULL
analyzed	NULL
,	NULL
a	NULL
similarly	NULL
high	NULL
affinity	NULL
for	NULL
human	NULL
or	NULL
rat	NULL
DBP	NULL
was	NULL
observed	NULL
(	NULL
29	NULL
)	NULL
.	NULL

This	NULL
could	NULL
even	NULL
be	NULL
exploited	NULL
for	NULL
the	NULL
production	NULL
100-	NULL
X~	NULL
,	NULL
X\	NULL
‘	NULL
x	NULL
L	NULL
e	NULL
9	NULL
|-F-	NULL
2	NULL
sol-	NULL
&	NULL
2	NULL
a	NULL
|	NULL
m	NULL
x	NULL
1	NULL
1	NULL
1	NULL
L	NULL
L	NULL
i	NULL
19-®	NULL
10	NULL
``	NULL
10°	NULL
``	NULL
10	NULL
``	NULL
197*	NULL
10°5	NULL
10,25-	NULL
(	NULL
OM	NULL
}	NULL
;	NULL
D	NULL
;	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
)	NULL
BOUND/UNBOUND	NULL
(	NULL
%	NULL
)	NULL
1	NULL
L	NULL
1	NULL
19°	NULL
10°	NULL
19°	NULL
107	NULL
19	NULL
%	NULL
10°	NULL
10,25-	NULL
(	NULL
OH	NULL
}	NULL
;	NULL
D	NULL
;	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Affinity	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
from	NULL
rat	NULL
duodenal	NULL
mucosa	NULL
for	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
(	NULL
@	NULL
--	NULL
®	NULL
)	NULL
and	NULL
its	NULL
C-11-substituted	NULL
analogs	NULL
.	NULL

For	NULL
details	NULL
,	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Upper	NULL
panel	NULL
,	NULL
analogs	NULL
with	NULL
a	NULL
single	NULL
carbon	NULL
substitution	NULL
.	NULL

--	NULL
f	NULL
,	NULL
11	NULL
«	NULL
-methyl-1a,25~	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
;	NULL
O	NULL
--	NULL
C	NULL
,	NULL
x	NULL
--	NULL
x	NULL
,	NULL
11a-hydroxy-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
A	NULL
--	NULL
A	NULL
,	NULL
11a-fluoromethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Lower	NULL
panel	NULL
,	NULL
analogs	NULL
with	NULL
more	NULL
than	NULL
one	NULL
carbon	NULL
substitution	NULL
on	NULL
C-11	NULL
.	NULL

@	NULL
-	NULL
-	NULL
-	NULL
#	NULL
,	NULL
lla-ethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
;	NULL
x-	NULL
-	NULL
-x	NULL
;	NULL
lla-vinyl-1a,25~	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
;	NULL
*-	NULL
-	NULL
-	NULL
#	NULL
,	NULL
11a-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
G-	NULL
-	NULL
-C	NULL
,	NULL
116-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
M-	NULL
-	NULL
-l	NULL
,	NULL
11a-phenyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
;	NULL
O-	NULL
-	NULL
-C	NULL
,	NULL
118-phenyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

100	NULL
80	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Binding	NULL
of	NULL
(	NULL
@	NULL
--	NULL
@	NULL
)	NULL
and	NULL
its	NULL
C-11-substituted	NULL
60	NULL
analogs	NULL
to	NULL
purified	NULL
human	NULL
DBP	NULL
measured	NULL
at	NULL
4°C	NULL
and	NULL
pH	NULL
7.4	NULL
.	NULL

For	NULL
details	NULL
,	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Left	NULL
panel	NULL
,	NULL
binding	NULL
of	NULL
analogs	NULL
with	NULL
a	NULL
40	NULL
single	NULL
carbon	NULL
substitution	NULL
on	NULL
C-11	NULL
;	NULL
right	NULL
panel	NULL
,	NULL
binding	NULL
of	NULL
analogs	NULL
with	NULL
more	NULL
than	NULL
one	NULL
C	NULL
substitution	NULL
on	NULL
C-11	NULL
.	NULL

The	NULL
symbols	NULL
20	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

B/B	NULL
,	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
1,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
,	NULL
bound/bound	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
unlabeled	NULL
steroid	NULL
.	NULL

B/Be	NULL
(	NULL
%	NULL
)	NULL
1	NULL
1	NULL
10°	NULL
107	NULL
``	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
0	NULL
,	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
}	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
of	NULL
an	NULL
**I-labeled	NULL
analog	NULL
,	NULL
11	NULL
«	NULL
-	NULL
[	NULL
2-O-	NULL
(	NULL
meta-'*	NULL
``	NULL
I-tyramidosucci-noyl	NULL
)	NULL
-ethyl	NULL
]	NULL
-25-OH-D	NULL
;	NULL
,	NULL
for	NULL
radioassay	NULL
of	NULL
25-0O0H-D	NULL
;	NULL
.	NULL
``	NULL

The	NULL
affinity	NULL
of	NULL
further	NULL
metabolites	NULL
or	NULL
analogs	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
for	NULL
DBP	NULL
has	NULL
not	NULL
been	NULL
extensively	NULL
studied	NULL
before	NULL
,	NULL
but	NULL
very	NULL
few	NULL
have	NULL
increased	NULL
affinity	NULL
for	NULL
this	NULL
plasma	NULL
protein	NULL
.	NULL

The	NULL
two	NULL
stereoisomers	NULL
of	NULL
14,24,25-trihydroxyvitamin	NULL
D	NULL
;	NULL
lose	NULL
about	NULL
half	NULL
of	NULL
their	NULL
affinity	NULL
for	NULL
rat	NULL
DBP	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
natural	NULL
and	NULL
unnatural	NULL
stereoisomers	NULL
of	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
-26,23-lactone	NULL
have	NULL
a	NULL
nearly	NULL
3-fold	NULL
increase	NULL
in	NULL
binding	NULL
to	NULL
rat	NULL
DBP	NULL
,	NULL
but	NULL
their	NULL
binding	NULL
to	NULL
the	NULL
chick	NULL
intestinal	NULL
receptor	NULL
is	NULL
only	NULL
0.6	NULL
or	NULL
3	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
31	NULL
)	NULL
A	NULL
more	NULL
recent	NULL
analog	NULL
,	NULL
26-	NULL
(	NULL
3-hydroxypropyl	NULL
)	NULL
-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
has	NULL
a	NULL
2-fold	NULL
increase	NULL
in	NULL
DBP	NULL
binding	NULL
but	NULL
an	NULL
8-fold	NULL
decrease	NULL
in	NULL
chick	NULL
intestinal	NULL
receptor	NULL
binding	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Our	NULL
present	NULL
data	NULL
thus	NULL
demonstrate	NULL
that	NULL
C-11	NULL
substitutions	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
have	NULL
variable	NULL
effects	NULL
on	NULL
receptor	NULL
binding	NULL
but	NULL
do	NULL
not	NULL
sterically	NULL
hinder	NULL
the	NULL
binding	NULL
and	NULL
,	NULL
on	NULL
the	NULL
contrary	NULL
,	NULL
can	NULL
even	NULL
enhance	NULL
up	NULL
to	NULL
4-fold	NULL
the	NULL
binding	NULL
affinity	NULL
towards	NULL
DBP	NULL
.	NULL

This	NULL
probably	NULL
implies	NULL
that	NULL
C-11	NULL
extensions	NULL
stick	NULL
outside	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
vitamin	NULL
D-DBP	NULL
complex	NULL
but	NULL
nevertheless	NULL
create	NULL
new	NULL
interactions	NULL
that	NULL
stabilize	NULL
the	NULL
complex	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
C-11	NULL
substitutions	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
normal	NULL
leucocytes	NULL
differed	NULL
from	NULL
the	NULL
results	NULL
obtained	NULL
on	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
promyelocytic	NULL
tumor	NULL
cells	NULL
.	NULL

As	NULL
described	NULL
before	NULL
(	NULL
9	NULL
,	NULL
23	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
proliferation	NULL
of	NULL
leukemic	NULL
cells	NULL
required	NULL
an	NULL
about	NULL
100-fold	NULL
higher	NULL
concentration	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
than	NULL
necessary	NULL
for	NULL
normal	NULL
mononuclear	NULL
cells	NULL
.	NULL

Of	NULL
all	NULL
the	NULL
C-11-substituted	NULL
analogs	NULL
,	NULL
only	NULL
11a-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
markedly	NULL
inhibited	NULL
PBMC	NULL
proliferation	NULL
,	NULL
doing	NULL
so	NULL
slightly	NULL
better	NULL
in	NULL
the	NULL
absence	NULL
than	NULL
the	NULL
presence	NULL
of	NULL
DBP	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
several	NULL
C-11	NULL
analogs	NULL
markedly	NULL
inhibited	NULL
proliferation	NULL
and	NULL
induced	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
differentiation	NULL
(	NULL
NBT	NULL
reduction	NULL
)	NULL
was	NULL
a	NULL
mirror	NULL
image	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
vitamin	NULL
D	NULL
analogs	NULL
on	NULL
proliferation	NULL
(	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Most	NULL
C-11-substituted	NULL
analogs	NULL
thus	NULL
have	NULL
higher	NULL
effects	NULL
on	NULL
differentiation	NULL
and	NULL
proliferation	NULL
of	NULL
promyeloid	NULL
leukemia	NULL
cells	NULL
than	NULL
on	NULL
normal	NULL
mixed	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
discrepancy	NULL
is	NULL
not	NULL
clear	NULL
,	NULL
but	NULL
differences	NULL
in	NULL
receptor	NULL
structure	NULL
,	NULL
regulation	NULL
,	NULL
or	NULL
accessibility	NULL
,	NULL
postreceptor	NULL
differences	NULL
,	NULL
or	NULL
simple	NULL
differences	NULL
in	NULL
the	NULL
metabolism	NULL
of	NULL
the	NULL
vitamin	NULL
analogs	NULL
are	NULL
all	NULL
plausible	NULL
.	NULL

The	NULL
bone-resorbing	NULL
effect	NULL
of	NULL
the	NULL
new	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
were	NULL
in	NULL
line	NULL
with	NULL
their	NULL
affinity	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
and	NULL
their	NULL
effect	NULL
on	NULL
the	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
concordance	NULL
with	NULL
inhibition	NULL
of	NULL
PBMC	NULL
proliferation	NULL
was	NULL
rather	NULL
poor	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

This	NULL
concordance	NULL
in	NULL
differentiating	NULL
effects	NULL
on	NULL
HL-60	NULL
cells	NULL
and	NULL
bone	NULL
resorption	NULL
is	NULL
not	NULL
unexpected	NULL
*	NULL
R.	NULL
Bouillon	NULL
and	NULL
E.	NULL
Van	NULL
Herck	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

100	NULL
80	NULL
L	NULL
10°*	NULL
10°	NULL
10°	NULL
10	NULL
``	NULL
10	NULL
%	NULL
10°	NULL
1a,25-	NULL
(	NULL
0H	NULL
}	NULL
;	NULL
0	NULL
;	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
)	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
[	NULL
MIThymidine	NULL
incorporation	NULL
(	NULL
%	NULL
)	NULL
Lypi	NULL
i	NULL
i	NULL
L_	NULL
J	NULL
10~	NULL
``	NULL
10°	NULL
``	NULL
10°	NULL
``	NULL
10°	NULL
107	NULL
``	NULL
ta,25-	NULL
(	NULL
0H	NULL
}	NULL
;	NULL
0	NULL
;	NULL
,	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
)	NULL
UHIThymidine	NULL
incorporation	NULL
(	NULL
%	NULL
)	NULL
1	NULL
L	NULL
1	NULL
F	NULL
19°°	NULL
10°	NULL
``	NULL
10	NULL
``	NULL
19	NULL
``	NULL
1	NULL
@	NULL
,25-	NULL
(	NULL
0H	NULL
}	NULL
;	NULL
0	NULL
;	NULL
,	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
}	NULL
1,11	NULL
10°	NULL
``	NULL
3049	NULL
[	NULL
B	NULL
i	NULL
'\	NULL
t	NULL
x	NULL
3	NULL
100ly	NULL
§	NULL
0	NULL
[	NULL
~	NULL
‘	NULL
5	NULL
a	NULL
&	NULL
3	NULL
.6	NULL
#	NULL
[	NULL
€	NULL
&	NULL
sol	NULL
4	NULL
I	NULL
’	NULL
L	NULL
‘	NULL
R	NULL
1	NULL
1	NULL
__	NULL
}	NULL
10°	NULL
``	NULL
19°®	NULL
19°*	NULL
19	NULL
``	NULL
107	NULL
or	NULL
analog	NULL
(	NULL
M	NULL
)	NULL
50	NULL
)	NULL
-	NULL
.	NULL

.	NULL

|	NULL
(	NULL
MlThymidine	NULL
incorporation	NULL
(	NULL
%	NULL
)	NULL
gpl	NULL
1	NULL
.	NULL

1	NULL
1	NULL
_J	NULL
10°	NULL
``	NULL
10°	NULL
``	NULL
10°	NULL
10°	NULL
107	NULL
1,25-	NULL
(	NULL
0H	NULL
}	NULL
,	NULL
D	NULL
,	NULL
or	NULL
analog	NULL
{	NULL
M	NULL
)	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
and	NULL
its	NULL
C-11-substituted	NULL
analogs	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
phytohem-agglutin-stimulated	NULL
mixed	NULL
peripheral	NULL
human	NULL
blood	NULL
lymphocytes	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
[	NULL
*Hjthymidine	NULL
incorporation	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
done	NULL
in	NULL
replicates	NULL
of	NULL
six	NULL
in	NULL
microcultures	NULL
of	NULL
PBMC	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
,	NULL
A	NULL
,	NULL
studies	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
hDBP	NULL
-free	NULL
serum	NULL
;	NULL
B	NULL
,	NULL
studies	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
hDBP	NULL
(	NULL
7.5	NULL
uM	NULL
)	NULL
by	NULL
using	NULL
DBP	NULL
-free	NULL
human	NULL
serum	NULL
reconstituted	NULL
with	NULL
purified	NULL
hDBP	NULL
.	NULL

The	NULL
symbols	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

NBT	NULL
REDUCTION	NULL
(	NULL
%	NULL
)	NULL
(	NULL
~	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
107°	NULL
-	NULL
ao~	NULL
``	NULL
_	NULL
107	NULL
``	NULL
_	NULL
107°	NULL
1ar.2_	NULL
‘	NULL
>	NULL
—	NULL
(	NULL
OH	NULL
)	NULL
2D3	NULL
or	NULL
ANALOG	NULL
CONCENTRATION	NULL
(	NULL
M	NULL
)	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
2D	NULL
;	NULL
and	NULL
three	NULL
of	NULL
its	NULL
C-11-substituted	NULL
analogs	NULL
on	NULL
the	NULL
differentiation	NULL
and	NULL
proliferation	NULL
of	NULL
HL-60	NULL
cells	NULL
.	NULL

The	NULL
differentiating	NULL
effect	NULL
was	NULL
evaluated	NULL
by	NULL
NBT	NULL
reduction	NULL
,	NULL
and	NULL
the	NULL
antiproliferative	NULL
effect	NULL
was	NULL
evaluated	NULL
by	NULL
[	NULL
°HJthy-midine	NULL
incorporation	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

@	NULL
,	NULL
M	NULL
,	NULL
11	NULL
a-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
x	NULL
,	NULL
11a-vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
;	NULL
A	NULL
,	NULL
11a-fluoromethyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
Ds	NULL
.	NULL

since	NULL
bone	NULL
marrow	NULL
monocyte	NULL
cells	NULL
,	NULL
with	NULL
precursors	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
HL-60	NULL
cells	NULL
,	NULL
are	NULL
supposed	NULL
to	NULL
be	NULL
at	NULL
the	NULL
origin	NULL
of	NULL
osteoclasts	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
and	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
stimulate	NULL
the	NULL
differentiation	NULL
of	NULL
these	NULL
precursors	NULL
into	NULL
more	NULL
mature	NULL
osteo-clasts	NULL
.	NULL

For	NULL
unexplained	NULL
reasons	NULL
,	NULL
however	NULL
,	NULL
no	NULL
such	NULL
correlation	NULL
was	NULL
found	NULL
for	NULL
other	NULL
vitamin	NULL
D	NULL
analogs	NULL
with	NULL
side	NULL
chain	NULL
modifications	NULL
(	NULL
e.g	NULL
.	NULL

A	NULL
``	NULL
-24,24,24-trihomo-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
(	NULL
85	NULL
)	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
effects	NULL
of	NULL
C-11-substituted	NULL
vitamin	NULL
D	NULL
analogs	NULL
were	NULL
tested	NULL
both	NULL
for	NULL
serum	NULL
and	NULL
bone	NULL
calcium	NULL
responses	NULL
and	NULL
for	NULL
the	NULL
effect	NULL
on	NULL
serum	NULL
osteocalcin	NULL
and	NULL
duodenal	NULL
calbindin	NULL
D-28K	NULL
concentrations	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
for	NULL
all	NULL
these	NULL
parameters	NULL
,	NULL
but	NULL
the	NULL
dose-response	NULL
curve	NULL
for	NULL
the	NULL
vitamin	NULL
D-responsive	NULL
proteins	NULL
was	NULL
much	NULL
steeper	NULL
and	NULL
allowed	NULL
a	NULL
better	NULL
evaluation	NULL
of	NULL
the	NULL
relative	NULL
potency	NULL
.	NULL

The	NULL
difference	NULL
between	NULL
the	NULL
stereoisomers	NULL
of	NULL
11-methyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
receptor	NULL
binding	NULL
and	NULL
HL-60	NULL
cell	NULL
proliferation	NULL
in	NULL
vitro	NULL
was	NULL
confirmed	NULL
in	NULL
vivo	NULL
for	NULL
effects	NULL
on	NULL
calcium	NULL
metabolism	NULL
(	NULL
Table	NULL
I	NULL
and	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
all	NULL
C-11-substituted	NULL
analogs	NULL
in	NULL
vivo	NULL
was	NULL
2-10-fold	NULL
lower	NULL
than	NULL
the	NULL
effects	NULL
on	NULL
bone	NULL
resorption	NULL
in	NULL
vitro	NULL
and	NULL
lower	NULL
than	NULL
could	NULL
be	NULL
expected	NULL
from	NULL
their	NULL
receptor-binding	NULL
properties	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
was	NULL
most	NULL
obvious	NULL
for	NULL
3050	NULL
and	NULL
1l1a-vinyl-1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Increased	NULL
DBP	NULL
binding	NULL
could	NULL
have	NULL
decreased	NULL
the	NULL
immediate	NULL
availability	NULL
of	NULL
vitamin	NULL
D	NULL
analogs	NULL
in	NULL
vivo	NULL
,	NULL
but	NULL
this	NULL
would	NULL
normally	NULL
be	NULL
offset	NULL
by	NULL
their	NULL
longer	NULL
half-lives	NULL
.	NULL

Analogs	NULL
with	NULL
poor	NULL
receptor	NULL
binding	NULL
,	NULL
k	NULL
40	NULL
7	NULL
30	NULL
;	NULL
20	NULL
%	NULL
*	NULL
``	NULL
Ca	NULL
RELEASE	NULL
0	NULL
~~	NULL
-r	NULL
1	NULL
107	NULL
``	NULL
107	NULL
10	NULL
``	NULL
10	NULL
``	NULL
%	NULL
``	NULL
Ca	NULL
RELEASE	NULL
a	NULL
0	NULL
40	NULL
t	NULL
*	NULL
/	NULL
20	NULL
at	NULL
=	NULL
=	NULL
-=	NULL
‘	NULL
;	NULL
~	NULL
-=-	NULL
Bee	NULL
cC	NULL
7	NULL
o	NULL
|-	NULL
-	NULL
7	NULL
r	NULL
w	NULL
'	NULL
0	NULL
10°	NULL
``	NULL
0	NULL
go	NULL
``	NULL
0	NULL
40	NULL
``	NULL
_	NULL
140	NULL
``	NULL
_	NULL
10	NULL
``	NULL
vitamin	NULL
0	NULL
metabolite	NULL
or	NULL
analog	NULL
{	NULL
M	NULL
}	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
and	NULL
its	NULL
analogs	NULL
on	NULL
in	NULL
vitro	NULL
bone	NULL
resorption	NULL
of	NULL
fetal	NULL
radii	NULL
and	NULL
ulnae	NULL
during	NULL
3-day	NULL
(	NULL
A	NULL
)	NULL
or	NULL
6-day	NULL
(	NULL
B	NULL
)	NULL
incubations	NULL
.	NULL

The	NULL
release	NULL
of	NULL
``	NULL
Ca	NULL
from	NULL
prelabeled	NULL
fetal	NULL
bone	NULL
is	NULL
measured	NULL
as	NULL
an	NULL
estimation	NULL
of	NULL
bone	NULL
resorption	NULL
.	NULL

The	NULL
symbols	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

P	NULL
0	NULL
Serum	NULL
Calcium	NULL
(	NULL
mg/100m1	NULL
)	NULL
on	NULL
T	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
as	NULL
expected	NULL
,	NULL
also	NULL
demonstrated	NULL
a	NULL
low	NULL
biological	NULL
effect	NULL
in	NULL
vivo	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Previous	NULL
data	NULL
on	NULL
vitamin	NULL
D	NULL
analogs	NULL
with	NULL
C	NULL
ring	NULL
modifications	NULL
are	NULL
limited	NULL
to	NULL
the	NULL
synthesis	NULL
of	NULL
a	NULL
few	NULL
1l1a-substituted-9	NULL
(	NULL
11	NULL
)	NULL
-dehydro-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
analogs	NULL
(	NULL
7	NULL
)	NULL
with	NULL
decreased	NULL
receptor	NULL
affinity	NULL
(	NULL
36	NULL
)	NULL
and	NULL
to	NULL
the	NULL
synthesis	NULL
of	NULL
11a-hydroxyvi-tamin	NULL
D	NULL
;	NULL
(	NULL
26	NULL
)	NULL
.	NULL

This	NULL
latter	NULL
compound	NULL
bound	NULL
slightly	NULL
better	NULL
to	NULL
DBP	NULL
than	NULL
vitamin	NULL
D	NULL
;	NULL
itself	NULL
but	NULL
displayed	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
a	NULL
low	NULL
affinity	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
.	NULL

No	NULL
direct	NULL
studies	NULL
of	NULL
its	NULL
further	NULL
hydroxylated	NULL
metabolites	NULL
were	NULL
performed	NULL
,	NULL
but	NULL
l1a	NULL
«	NULL
-hydroxyvitamin	NULL
D	NULL
;	NULL
showed	NULL
low	NULL
biological	NULL
activity	NULL
in	NULL
vivo	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Several	NULL
of	NULL
the	NULL
C-11-substituted	NULL
analogs	NULL
have	NULL
a	NULL
higher	NULL
affinity	NULL
for	NULL
hDBP	NULL
than	NULL
the	NULL
natural	NULL
hormone	NULL
and	NULL
still	NULL
retain	NULL
good	NULL
receptor-binding	NULL
properties	NULL
(	NULL
eg	NULL
.	NULL

11	NULL
«	NULL
-CH	NULL
;	NULL
-	NULL
,	NULL
11	NULL
«	NULL
-CH	NULL
;	NULL
F-	NULL
,	NULL
or	NULL
l1a-vinyl-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
.	NULL

No	NULL
natural	NULL
metabolite	NULL
has	NULL
such	NULL
properties	NULL
,	NULL
and	NULL
only	NULL
one	NULL
other	NULL
analog	NULL
approached	NULL
this	NULL
combination	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Increased	NULL
DBP	NULL
binding	NULL
is	NULL
expected	NULL
to	NULL
decrease	NULL
the	NULL
biological	NULL
effectiveness	NULL
,	NULL
as	NULL
has	NULL
been	NULL
demonstrated	NULL
repeatedly	NULL
in	NULL
vitro	NULL
(	NULL
36	NULL
)	NULL
,	NULL
but	NULL
can	NULL
otherwise	NULL
prolong	NULL
the	NULL
circulating	NULL
half-life	NULL
.	NULL

One	NULL
recent	NULL
analog	NULL
,	NULL
28-	NULL
(	NULL
3-hydroxypropyl	NULL
)	NULL
-1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
with	NULL
only	NULL
a	NULL
2-fold	NULL
increase	NULL
in	NULL
DBP	NULL
binding	NULL
and	NULL
an	NULL
8-fold	NULL
decrease	NULL
in	NULL
receptor	NULL
binding	NULL
,	NULL
increased	NULL
the	NULL
bone	NULL
mass	NULL
of	NULL
ovariectomized	NULL
rats	NULL
when	NULL
given	NULL
intermittently	NULL
twice	NULL
a	NULL
week	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Several	NULL
of	NULL
the	NULL
C-11-substituted	NULL
analogs	NULL
also	NULL
demonstrated	NULL
increased	NULL
DBP	NULL
binding	NULL
but	NULL
,	NULL
at	NULL
least	NULL
when	NULL
given	NULL
once	NULL
daily	NULL
,	NULL
this	NULL
did	NULL
not	NULL
increase	NULL
,	NULL
but	NULL
rather	NULL
decreased	NULL
,	NULL
their	NULL
biological	NULL
efficacy	NULL
.	NULL

Giving	NULL
it	NULL
more	NULL
intermittently	NULL
,	NULL
as	NULL
in	NULL
the	NULL
study	NULL
by	NULL
Okano	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
,	NULL
might	NULL
be	NULL
more	NULL
advantageous	NULL
.	NULL

Several	NULL
recent	NULL
analogs	NULL
of	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
retain	NULL
good	NULL
or	NULL
reasonable	NULL
receptor-binding	NULL
properties	NULL
but	NULL
,	NULL
contrary	NULL
to	NULL
our	NULL
C-11-substituted	NULL
analogs	NULL
,	NULL
display	NULL
markedly	NULL
decreased	NULL
DBP	NULL
binding	NULL
properties	NULL
.	NULL

Indeed	NULL
,	NULL
MC	NULL
903	NULL
or	NULL
calcipitriol	NULL
(	NULL
37	NULL
)	NULL
,	NULL
24,24	NULL
,	NULL
bishomo-1	NULL
@	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
23	NULL
,	NULL
29	NULL
,	NULL
35	NULL
)	NULL
,	NULL
22-oxa-1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
37	NULL
)	NULL
,	NULL
and	NULL
1	NULL
«	NULL
,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
-23-yne-D	NULL
;	NULL
(	NULL
89	NULL
)	NULL
all	NULL
retain	NULL
reasonably	NULL
good	NULL
(	NULL
>	NULL
10	NULL
%	NULL
compared	NULL
with	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
affinity	NULL
for	NULL
the	NULL
vitamin	NULL
D	NULL
receptor	NULL
but	NULL
display	NULL
a	NULL
low	NULL
affinity	NULL
for	NULL
DBP	NULL
(	NULL
10-1000-fold	NULL
decrease	NULL
)	NULL
.	NULL

This	NULL
probably	NULL
alters	NULL
their	NULL
pharma-cokinetics	NULL
and	NULL
allows	NULL
better	NULL
activity	NULL
when	NULL
applied	NULL
locally	NULL
(	NULL
e.g	NULL
.	NULL

for	NULL
psoriatic	NULL
lesions	NULL
(	NULL
41	NULL
)	NULL
)	NULL
or	NULL
induce	NULL
greater	NULL
effects	NULL
on	NULL
lympho-	NULL
e	NULL
100	NULL
a	NULL
&	NULL
2	NULL
_	NULL
/	NULL
g	NULL
g	NULL
N	NULL
Ti	NULL
“	NULL
“	NULL
‘	NULL
=='-='-.~	NULL
--	NULL
a	NULL
Q	NULL
~s	NULL
ba	NULL
50	NULL
n	NULL
i	NULL
®	NULL
€	NULL
(	NULL
1	NULL
1	NULL
L	NULL
1	NULL
_	NULL
_L	NULL
.	NULL

Fig	NULL
.	NULL

8	NULL
.	NULL

Effect	NULL
of	NULL
1a,25-	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
Ds	NULL
C	NULL
and	NULL
its	NULL
C-11-substituted	NULL
analogs	NULL
on	NULL
S	NULL
30	NULL
;	NULL
the	NULL
serum	NULL
concentration	NULL
of	NULL
calcium	NULL
g	NULL
and	NULL
osteocalcin	NULL
,	NULL
the	NULL
duodenal	NULL
con-	NULL
-	NULL
,	NULL
,	NULL
tent	NULL
of	NULL
calbindin	NULL
D-28K	NULL
,	NULL
and	NULL
the	NULL
S.	NULL
bone	NULL
calcium	NULL
content	NULL
after	NULL
10	NULL
days	NULL
320	NULL
of	NULL
daily	NULL
intramuscular	NULL
injection	NULL
in	NULL
x	NULL
vitamin	NULL
D-deficient	NULL
chicks	NULL
.	NULL

The	NULL
sym-	NULL
-	NULL
%	NULL
bols	NULL
are	NULL
the	NULL
same	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

‘	NULL
2	NULL
3	NULL
10	NULL
a	NULL
|	NULL
@	NULL
€	NULL
,	NULL
€	NULL
a	NULL
a	NULL
197	NULL
``	NULL
1a	NULL
,	NULL
25-	NULL
(	NULL
OH	NULL
)	NULL
3D3	NULL
or	NULL
analog	NULL
(	NULL
mol/day	NULL
)	NULL
,	NULL
*	NULL
1	NULL
--	NULL
£	NULL
]	NULL
a\	NULL
1	NULL
1	NULL
ces	NULL
L_	NULL
ro	NULL
8	NULL
as	NULL
2000	NULL
g	NULL
-	NULL
1500	NULL
-	NULL
1000	NULL
‘	NULL
f/tIIIIZZ	NULL
:	NULL
:	NULL
:	NULL
:	NULL
:	NULL
:	NULL
:	NULL
§	NULL
--	NULL
‘	NULL
*	NULL
~~500	NULL
{	NULL
tw/6u	NULL
)	NULL
ut3res0a3	NULL
y*	NULL
10°	NULL
``	NULL
10	NULL
°°	NULL
10	NULL
1a	NULL
,	NULL
25-	NULL
{	NULL
OH	NULL
)	NULL
,	NULL
D	NULL
,	NULL
or	NULL
analog	NULL
{	NULL
mol/day	NULL
)	NULL
107°	NULL
10	NULL
°	NULL
Vitamin	NULL
D	NULL
Analogs	NULL
with	NULL
C-ring	NULL
Modifications	NULL
3051	NULL
cyte	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
or	NULL
parathyroid	NULL
function	NULL
(	NULL
38	NULL
)	NULL
than	NULL
on	NULL
serum	NULL
calcium	NULL
homeostasis	NULL
.	NULL

Several	NULL
C-11-substituted	NULL
analogs	NULL
were	NULL
more	NULL
potent	NULL
on	NULL
leukemic	NULL
cell	NULL
differentiation	NULL
and	NULL
proliferation	NULL
than	NULL
on	NULL
normal	NULL
leucocytes	NULL
in	NULL
vitro	NULL
or	NULL
calcium	NULL
metabolism	NULL
in	NULL
vivo	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
was	NULL
,	NULL
however	NULL
,	NULL
smaller	NULL
than	NULL
that	NULL
observed	NULL
for	NULL
several	NULL
analogs	NULL
with	NULL
side	NULL
chain	NULL
modifications	NULL
.	NULL

Possible	NULL
therapeutic	NULL
effects	NULL
in	NULL
vivo	NULL
on	NULL
cancer	NULL
growth	NULL
or	NULL
differentiation	NULL
therefore	NULL
will	NULL
depend	NULL
on	NULL
further	NULL
specific	NULL
testing	NULL
.	NULL

Acknowledgment-A	NULL
.	NULL

W.	NULL
Norman	NULL
kindly	NULL
provided	NULL
the	NULL
chick	NULL
calbindin	NULL
D-28K	NULL
protein	NULL
for	NULL
radioimmunoassay	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Reichel	NULL
,	NULL
H.	NULL
,	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

320	NULL
,	NULL
980-991	NULL
2	NULL
.	NULL

Deluca	NULL
,	NULL
H.	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

192	NULL
,	NULL
224-236	NULL
3	NULL
.	NULL

Bouillon	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Van	NULL
Baelen	NULL
,	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Saudi	NULL
Med	NULL
.	NULL

J	NULL
.	NULL

10	NULL
,	NULL
260-266	NULL
4	NULL
.	NULL

Suda	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

192	NULL
,	NULL
214-220	NULL
5	NULL
.	NULL

Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Provvedini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Endocrinol	NULL
.	NULL

48	NULL
,	NULL
113-122	NULL
6	NULL
.	NULL

Teutsch	NULL
,	NULL
G.	NULL
,	NULL
Ojasoo	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Raynaud	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

31	NULL
,	NULL
549-565	NULL
7	NULL
.	NULL

Pumar	NULL
,	NULL
C.	NULL
,	NULL
Aurrecoechea	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Gibbs	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
Okamura	NULL
,	NULL
W.	NULL
H.	NULL
(	NULL
1988	NULL
)	NULL
in	NULL
Vitamin	NULL
D	NULL
Molecular	NULL
,	NULL
Cellular	NULL
and	NULL
Clinical	NULL
Endocrinology	NULL
(	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Schaefer	NULL
,	NULL
K.	NULL
,	NULL
Gri-goleit	NULL
,	NULL
H.-G.	NULL
,	NULL
and	NULL
Herrath	NULL
,	NULL
D.	NULL
v.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

54-56	NULL
,	NULL
Walter	NULL
de	NULL
Gruyter	NULL
,	NULL
Berlin	NULL
8	NULL
.	NULL

Van	NULL
Baelen	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Bouillon	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
in	NULL
Binding	NULL
Proteins	NULL
of	NULL
Steroid	NULL
Hormones	NULL
(	NULL
Forest	NULL
,	NULL
M.	NULL
(	NULL
G.	NULL
,	NULL
and	NULL
Pugeat	NULL
,	NULL
M.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

69-83	NULL
,	NULL
John	NULL
Libbey	NULL
Eurotext	NULL
,	NULL
Paris	NULL
9	NULL
.	NULL

Vanham	NULL
,	NULL
G.	NULL
,	NULL
Van	NULL
Baelen	NULL
,	NULL
H.	NULL
,	NULL
Tan	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
and	NULL
Bouillon	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

29	NULL
,	NULL
381-386	NULL
10	NULL
.	NULL

Mascarenas	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Mourino	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Castedo	NULL
,	NULL
L.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

51	NULL
,	NULL
1269-1272	NULL
11	NULL
.	NULL

Baggiolini	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Iacobelli	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hennessy	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Batcho	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sereno	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Uskokovic	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

51	NULL
,	NULL
3098-3108	NULL
12	NULL
.	NULL

Sardina	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Mourino	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Castedo	NULL
,	NULL
L.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

51	NULL
,	NULL
1264-1269	NULL
13	NULL
.	NULL

Partridge	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Faber	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Uskokovic	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1974	NULL
)	NULL
Helv	NULL
.	NULL

Chim	NULL
.	NULL

Acta	NULL
57	NULL
,	NULL
764-771	NULL
14	NULL
.	NULL

Reich	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Reich	NULL
,	NULL
I.	NULL
L.	NULL
,	NULL
and	NULL
Renga	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1973	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Chem	NULL
.	NULL

Soc	NULL
.	NULL

95	NULL
,	NULL
5813-5815	NULL
15	NULL
.	NULL

Reich	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Renga	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Reich	NULL
,	NULL
I.	NULL
L.	NULL
(	NULL
1974	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

39	NULL
,	NULL
2133-2135	NULL
16	NULL
.	NULL

Posner	NULL
,	NULL
G.	NULL
H.	NULL
(	NULL
1972	NULL
)	NULL
Org	NULL
.	NULL

React	NULL
.	NULL

19	NULL
,	NULL
1-113	NULL
17	NULL
.	NULL

Lipshutz	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Wilhelm	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
and	NULL
Kozlowski	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Tetrahedon	NULL
40	NULL
,	NULL
5005-5038	NULL
18	NULL
.	NULL

Lipshutz	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Synthesis	NULL
,	NULL
325-341	NULL
19	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

Cox	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Terpinski	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Lawrynowiez	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

49	NULL
,	NULL
3216-3219	NULL
Ireland	NULL
,	NULL
R.	NULL
,	NULL
Anderson	NULL
,	NULL
R.	NULL
,	NULL
Badoud	NULL
,	NULL
R.	NULL
,	NULL
Fitzsimmons	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Mc-Garvey	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Thaisrivongs	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Wilcox	NULL
,	NULL
C.	NULL
S.	NULL
(	NULL
1983	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Chem	NULL
.	NULL

Soc	NULL
.	NULL

105	NULL
,	NULL
1988-2006	NULL
Bouillon	NULL
,	NULL
R.	NULL
,	NULL
Van	NULL
Baelen	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
De	NULL
Moor	NULL
,	NULL
P.	NULL
(	NULL
1980	NULL
)	NULL
J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

18	NULL
,	NULL
1029-1034	NULL
Pols	NULL
,	NULL
H.	NULL
A.	NULL
P.	NULL
,	NULL
Schilte	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Visser	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Birkenhiger	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1987	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
931	NULL
,	NULL
115-119	NULL
Ostrem	NULL
,	NULL
V.	NULL
K.	NULL
,	NULL
Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
Prahl	NULL
,	NULL
J.	NULL
,	NULL
Deluca	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Ikekawa	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

84	NULL
,	NULL
2610-2614	NULL
Raisz	NULL
,	NULL
L.	NULL
G.	NULL
(	NULL
1965	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

44	NULL
,	NULL
103-116	NULL
Pols	NULL
,	NULL
H.	NULL
A.	NULL
P.	NULL
,	NULL
Schilte	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Nijweide	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Visser	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Birkenhager	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1984	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

125	NULL
,	NULL
265-272	NULL
Revelle	NULL
,	NULL
L.	NULL
,	NULL
Solan	NULL
,	NULL
V.	NULL
,	NULL
Londowski	NULL
,	NULL
J.	NULL
,	NULL
Bollman	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Kumar	NULL
,	NULL
R.	NULL
(	NULL
1984	NULL
)	NULL
Biochemistry	NULL
28	NULL
,	NULL
1983-1987	NULL
Kawakami	NULL
,	NULL
M.	NULL
,	NULL
Imawari	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Dewitt-Goodman	NULL
,	NULL
S.	NULL
(	NULL
1979	NULL
)	NULL
J.	NULL
Biochem	NULL
.	NULL

179	NULL
,	NULL
413-423	NULL
Haddad	NULL
,	NULL
J.	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
in	NULL
Bone	NULL
and	NULL
Mineral	NULL
Research	NULL
(	NULL
Peck	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
ed	NULL
)	NULL
Vol	NULL
.	NULL

V	NULL
,	NULL
pp	NULL
.	NULL

281-308	NULL
,	NULL
Elsevier	NULL
Science	NULL
Publishers	NULL
,	NULL
Amsterdam	NULL
Bouillon	NULL
,	NULL
R.	NULL
,	NULL
Allewaert	NULL
,	NULL
K.	NULL
,	NULL
Xiang	NULL
,	NULL
D.	NULL
Z.	NULL
,	NULL
Vandewalle	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
De	NULL
Clercq	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Bone	NULL
Miner	NULL
.	NULL

Res	NULL
.	NULL

4	NULL
,	NULL
Suppl	NULL
.	NULL

1	NULL
,	NULL
734	NULL
(	NULL
Abstr	NULL
.	NULL
)	NULL

Mallon	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Matuszewski	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Sheppard	NULL
,	NULL
H.	NULL
(	NULL
1980	NULL
)	NULL
J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

13	NULL
,	NULL
409-413	NULL
Wilhelm	NULL
,	NULL
F.	NULL
,	NULL
Mayer	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

2883	NULL
,	NULL
322-329	NULL
Okano	NULL
,	NULL
T.	NULL
,	NULL
Tsugawa	NULL
,	NULL
N.	NULL
,	NULL
Masuda	NULL
,	NULL
S.	NULL
,	NULL
Takeuchi	NULL
,	NULL
A.	NULL
,	NULL
Kobayashi	NULL
,	NULL
T.	NULL
,	NULL
Takita	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Nishii	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

163	NULL
,	NULL
1444-1449	NULL
Ko	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Bernard	NULL
,	NULL
G.	NULL
W.	NULL
(	NULL
1981	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Anat	NULL
.	NULL

161	NULL
,	NULL
415-425	NULL
Yoneda	NULL
,	NULL
T.	NULL
,	NULL
Mundy	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Roodman	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Bone	NULL
Miner	NULL
.	NULL

Res	NULL
.	NULL

4	NULL
,	NULL
Supple	NULL
.	NULL

1	NULL
,	NULL
559	NULL
(	NULL
Abstr	NULL
.	NULL
)	NULL

Paulson	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Perlman	NULL
,	NULL
K.	NULL
,	NULL
Deluca	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
and	NULL
Stern	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Am	NULL
.	NULL

J	NULL
.	NULL

Bone	NULL
Miner	NULL
.	NULL

Res	NULL
.	NULL

5	NULL
,	NULL
201-206	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Koeefler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Bishop	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Collins	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
Sergeev	NULL
,	NULL
I.	NULL
,	NULL
Zhou	NULL
,	NULL
L.-X	NULL
.	NULL

,	NULL
Nemere	NULL
,	NULL
L.	NULL
,	NULL
Zhou	NULL
,	NULL
J.	NULL
,	NULL
Henry	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Okamura	NULL
,	NULL
W.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
in	NULL
Vitamin	NULL
D	NULL
,	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Endocrinology	NULL
.	NULL

Proceedings	NULL
of	NULL
the	NULL
8th	NULL
Vitamin	NULL
D	NULL
Workshop	NULL
(	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Bouillon	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Thomasset	NULL
,	NULL
M.	NULL
,	NULL
eds	NULL
)	NULL
Walter	NULL
de	NULL
Gruyter	NULL
,	NULL
Berlin	NULL
Bouillon	NULL
,	NULL
R.	NULL
,	NULL
Van	NULL
Baelen	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
De	NULL
Moor	NULL
,	NULL
P.	NULL
(	NULL
1986	NULL
)	NULL
in	NULL
Binding	NULL
Proteins	NULL
of	NULL
Steroid	NULL
Hormones	NULL
(	NULL
Forest	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
and	NULL
Pugeat	NULL
,	NULL
M.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

333-356	NULL
,	NULL
John	NULL
Libbey	NULL
Eurotext	NULL
,	NULL
Paris	NULL
Binderup	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Bramm	NULL
,	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

37	NULL
,	NULL
889-895	NULL
Brown	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Ritter	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Finch	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Morrissey	NULL
,	NULL
J.	NULL
,	NULL
Martin	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Murayama	NULL
,	NULL
E.	NULL
,	NULL
Nishii	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Slatopolsky	NULL
,	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84	NULL
,	NULL
728-732	NULL
Zhou	NULL
,	NULL
J.-Y	NULL
.	NULL

,	NULL
Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Lubbert	NULL
,	NULL
M.	NULL
,	NULL
Collins	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
Usko-koviec	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Koeffler	NULL
,	NULL
H.	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Blood	NULL
74	NULL
,	NULL
82-93	NULL
Kragballe	NULL
,	NULL
K.	NULL
,	NULL
Beck	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
Sogaard	NULL
,	NULL
H.	NULL
(	NULL
1988	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Der-matol	NULL
.	NULL

119	NULL
,	NULL
223-280	NULL

